Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Colorectal Neoplasms

• Investigate the Efficacy of Chemotherapy in Patients With Positive ctDNA After Surgery and Adjuvant Chemotherapy for a Stage III Colorectal Cancer
• A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers
• Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer
• Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer
• Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer
• caBozantinib in Pre-treated pAtients With Metastatic COlorectal Cancer.
• Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC
• Cadonilimab + FOLFOX Versus FOLFOX in the Neoadjuvant Treatment of pMMR/MSS Locally Advanced Colorectal Cancer
• Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
• Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer
• A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
• Clinical Study of Dexmedetomidine Administered Intranasally to Relieve Perioperative Anxiety and Depression in Patients With Colorectal Tumors
• Bemalenograstim Alfa for the Prevention in Patients With Colorectal Cancer/Pancreatic Cancer
• Sulfasalazine in Patients With Metastatic Colorectal Cancer
• A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
• Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer
• Pilot Window of Opportunity Trial (POET)
• Study of RMC-6291 in Combination With RMC-6236 in Participants With Advanced KRAS G12C Mutant Solid Tumors
• Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer
• Crisaborole Ointment for Skin Toxicity Induced by Cetuximab
• Study of Fuquinitinib Combined With Capecitabine First-line Maintenance in the Treatment of Metastatic Colorectal Cancer
• Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer
• Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizu
• Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mu
• Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
• Total Neoadjuvant Treatment for pMMR Locally Advanced Low Rectal Cancer: Anti-PD-1 Antibody With FOLFOXIRI and Preoperative Radiation Therapy
• The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer
• Prevention of Postoperative Recurrence and Metastasis of Colorectal Cancer by Comparing Huaier With Standard Treatment
• A Study of JMT101 in Patients With Metastatic Colorectal Cancer
• Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.
• Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
• Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors
• Fluorescent Probe VGT-309 to ID Cancerous Colorectal Lesions During Augmented Colonoscopy
• EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
• A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors
• The Safety of Ropivacaine TAP Block Combined With Intravenous Lidocaine in Patients Undergoing Colorectal Cancer Surgery
• Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer
• FIH, Bispecific CD276xCD3 Antibody CC-3 in Patients With Colorectal Cancer
• A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
• Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy
• KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer
• A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer
• A Study of SGN-EGFRd2 in Advanced Solid Tumors
• Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer
• A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies
• Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Met
• First in Human Study of TORL-3-600 in Participants With Advanced Cancer
• HTL0039732 in Participants With Advanced Solid Tumours
• Effect of Lidocaine on Postoperative Pain in Elderlypatients Undergoing Colorectal Cancer Surgery
• FOG-001 in Locally Advanced or Metastatic Solid Tumors
• Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors
• Combining Intratumoral Flu Vaccine and Systemic Pembrolizumab in Patients With Early pMMR Colorectal Cancer
• A First-In-Human Trial of pTTL in Advanced Colorectal Cancer
• Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)
• Serplulimab+Regorafenib +Hepatic Artery Bicarbonate Infusion in Patients With Colorectal Cancer and Liver Metastases
• Survival Benefit of Compound Kushen Injection in the Treatment of Advanced Colorectal Cancer
• 64Cu/68Ga Labelled EB-ss-CPT PET/CT Scan in Colorectal Cancer
• Multimodal Model for Efficacy Prediction Cetuximab in Colorectal Cancer Liver Metastasis Patient
• Effect of Losartan on the Incidence and Severity of Chemotherapy-Induced Mucositis in Gastrointestinal Cancer Patients
• A Study of RC198 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours
• Effect of Lidocaine Transdermal Patch as Add-On Therapy in Treatment of Oxaliplatin Induced Peripheral Neuropathy in Colorectal Cancer Patients : A Randomized , Double-Blind, Placebo Controlled Trial
• Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
• Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer
• Study of AK119 and AK 112 With or Without Chemotherapy for Colorectal Cancer Patients
• Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
• Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer
• The Efficacy and Safety of Fruquintinib Plus FOLFIRI as Second-line Treatment in RAS-mutated Metastatic Colorectal Cancer
• Multicenter, Single-arm, Open-label Phase II Clinical Study of Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer
• Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer
• Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
• Organoid-Guided Chemotherapy for Stage IV Colorectal Cancer
• ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer
• Efficacy and Safety of Regorafenib Maintenance Therapy in Patients With Metastatic Colorectal Cancer (mCRC)
• Cadonilimab in Locally Advanced MSI-H/dMMR Colorectal Cancer
• ctDNA-guided Adjuvant Chemotherapy in Liver Metastasis of Colorectal Cancer
• Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
• PD-L2 Targeting Nanobody Radiotracer for PET Imaging of Solid Tumor
• Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
• QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC
• Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer
• FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu ®) in the Treatment of Unresectable or Metastatic Colorectal Cancer
• Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients
• Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA
• Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases
• A Phase 1 Study of BDTX-4933 in Patients With BRAF and Select RAS/MAPK Mutation Positive Cancers
• DETERMINE Trial Treatment Arm 4: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations
• RC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal Cancer
• Open-Label, Multicenter, Phase 1/1b Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
• IV Ibuprofen vs Ketorolac in Post Operative Pain in Colorectal Cancer Surgeries in Obese Patient
• Efficacy and Safety of Triweekly Cetuximab in Combination With Capecitabine as First-line Maintenance Treatment for KRAS/BRAF Wild-type Metastatic Colorectal Cancer
• Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients
• DETERMINE Trial Treatment Arm 2: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficie
• Study of RO7515629 in Participants With HLA-G Positive Solid Tumors
• Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC
• DETERMINE Trial Treatment Arm 5: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
• First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours
• Hyperthermic Intraperitoneal Treatment of rmhTNF for CRCPM: Phase II Clinical Trial
• Metronidazole as Preoperative Therapy in CRC / FusoMetro-001
• SBRT Combined With Fruquintinib Plus PD-1/CTLA-4 Antibody for Third-line Treatment in mCRC
• ZN-c3 in Adult Participants With Metastatic Colorectal Cancer
• Effects of Dexmedetomidine/Lidocaine/Intrathecal Morphine on Cancer Metastasis Biomarker After Colorectal Surgery
• A Phase I Clinical Study of HS-10502 in Patients With Advanced Solid Tumors
• CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
• The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.
• Evaluation of SNDX-5613 in Participants With Colorectal Cancer and Other Solid Tumors
• Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer
• FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients
• A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
• Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
• Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer
• Efficacy, Tolerability and Safety of Intravenous D-VC With ATO in Patients With Advanced/Metastatic Colorectal Cancer
• Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detection
• Galunisertib Combined With Capecitabine in Advanced CRC With PM
• CAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD
• Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer
• COffee and Metabolites Modulating the Gut MicrobiomE in coloN canCER
• Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer
• A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer
• A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
• A Study of QBECO Versus Placebo in the Treatment of Colorectal Cancer That Has Spread to the Liver
• A Phase 1b Study of WU-NK-101 in Combination With Cetuximab
• Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
• Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy
• Disitamab Vedotin Combined With Fruquintinib for mCRC With HER2 Expression
• Fruquintinib Alternating With Bevacizumab Plus Capecitabine as Maintenance After First-line Treatment for Metastatic Colorectal Cancer
• A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer
• First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer
• The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer
• Study of BMF-219 in Adult Patients With Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer.
• Effect of Silymarin in Metastatic Colorectal Cancer Patients
• Testing ONC201 to Prevent Colorectal Cancer
• FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer
• TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer
• A Study of SOT101 in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer
• In Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung
• Electroporation and Immunotherapy in Metastatic Colorectal Cancer
• A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine in Participants With Unresectable or Metastatic Colorectal Cancer
• A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer Without Liver Metastases
• A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study
• Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutati
• Protective Effect of Pentoxifylline Against Chemotherapy Induced Toxicities in Patients With Colorectal Cancer
• EO4010 in Previously Treated Metastatic Colorectal Carcinoma
• Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver Metastases
• Evaluation of the Safety and Efficacy of Esperanza Extract (PA001)
• Preoperative Pembrolizumab Plus Bevacizumab Combined With Chemotherapy in Patients With pMMR/MSS Locally Advanced Colorectal Cancer
• Evaluate the Efficacy, Safety and Tolerability of HLX26 and HLX10 in Patients With Metastatic Colorectal Carcinoma That Have Received 3 Prior Lines of Therapy
• RC48 Plus Tislelizumab, Low-dose Capecitabine and Celecoxib for HER2-positive Metastatic Colorectal Cancer
• Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
• A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors
• Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer
• Combination Immunotherapy in Colorectal Cancer
• Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
• The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic Colorectal Cancer
• Efficacy and Safety of REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)
• Envafolimab Combined With Endostatin in Recurrent or Metastatic MSS-type Colorectal Cancer
• A Study of Safety and Efficacy of KFA115 Alone and KFA115 in Combination With Tislelizumab in Patients With Select Advanced Cancers
• VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer
• Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer
• A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
• A Phase 2 Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer
• A Prospective Multi-centered Randomized Controlled Trial on Fruquintinib in Combination With HAIC in the Treatment of Liver Metastatic Colorectal Cancer After Failure of Second-line Systematic Therapy
• Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer
• A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer
• Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer
• Phase II Study of Regorafenib and Toripalimab Combined With RFA in Patients With CRCLM
• Effect of Intravenous Infusion of Lidocaine on Patients Undergoing Radical Resection of Colorectal Tumors
• Phase 2 Study of DKN-01 in Colorectal Cancer
• mFOLFOX6 Combined With Dalpiciclib in Patients With Metastatic Colorectal Cancer
• Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial
• Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors
• Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
• Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer
• MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer
• Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer
• A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
• Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy
• Fruquintinib Sequential BEV+FOLFIRI vs. BEV+FOLFIRI Sequential Fruquintinib in Metastatic Colorectal Cancer
• A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery
• Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy
• Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer (AFFORD)
• Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients.
• Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer
• Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
• Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer
• Efficacy of Combination Immunotherapy in Patients With Metastatic Colorectal Cancer
• Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction Therapy
• a Pilot Study of Lidocaine Infusion for Postoperative Analgesia in Elderly Patients With Colorectal Cancer Surgery
• Exploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status
• Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy
• The CHAMP-study: The CHemopreventive Effect of Lithium in Familial AdenoMatous Polyposis
• The Colorectal Cancer Chemoprevention Acceleration and Improvement Platform (CRC-CHAMP) Study
• Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
• A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours
• Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial
• A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer
• Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)
• Evaluation of RMC-6236 in Subjects With Advanced Solid Tumors Harboring Specific Mutations in KRAS
• A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
• A Study Assessing the Interchangeability Between TRS003 and Bevacizumab® For CRC
• Systemic Therapy in Combination With Stereotactic Radiotherapy in Patients With Metastatic Colorectal Cancer up to 10 Metastatic Sites
• A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From Primary Gastric Cancer and Colorectal Cancer (CRC)
• Surufatinib Monotherapy for Advanced Colorectal Cancer in Later Line
• Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer
• Fruquintinib DDI Study With P-gp and BCRP Substrates
• Efficacy, Safety and Exploratory Clinical Study of Bevacizumab Combined With Oxaliplatin and TAS-102 in First-line Treatment of Advanced Colorectal Cancer
• mFOLXOX6 Versus FOLFIRI for Colorectal Patients Recurrence After Oxaplatin Based Adjuvant Chemotherapy
• Maintenance Anti-PD-1 Monoclonal Antibody + Capecitabine to Treat Metastatic Colorectal Cancer
• Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
• Tucatinib Combined With Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study
• Impact of FOLFIRINOX Chemotherapy in IV Stage Colorectal Cancer Patients Previously Exposed to Irinotecan, Fluoropyrimidine and Oxaliplatin
• Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases
• Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy
• EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer
• TAS-102 in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
• An Exploratory Study of Sequential Transarterial Chemoembolization With Lipiodol and Neoadjuvant Chemotherapy in the Treatment of Initial Unresectable Colorectal Cancer (CRC)
• Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer
• Study of Magrolimab Given Together With FOLFIRI/BEV in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)
• A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer
• Possible Protective Effect of Celecoxib Against Capecitabine Induced Hand and Foot Syndrome in Patients With Colorectal Cancer
• BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma
• GCC19CART for Patients With Metastatic Colorectal Cancer
• Triplet (FOLFOXIRI) vs. Doublet (FOLFOX or FOLFIRI) Regimen as a 1st Line Treatment in Metastatic Colorectal Carcinoma
• TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer
• Nivolumab and Ipilimumab in Patients With dMMR and/or MSI Metastatic Colorectal Cancer Resistant to Anti-PD1 Monotherapy
• Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC
• CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy
• Study on the Prevention of Dermal Toxicity Caused by Regorafenib by Traditional Chinese Medicine TDX105
• Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms
• Phase II Study Evaluating the Efficacy of M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma
• Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC)
• FMT Combined With Immune Checkpoint Inhibitor and TKI in the Treatment of CRC Patients With Advanced Stage
• Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer
• Tirelizumab Combined With Cetuximab and Irinotecan vs Third-line Regimens in the Treatment of Refractory mCRC
• Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer
• Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer
• A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
• A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
• Feasibility Study of Lidocaine Infusion During Bowel Cancer Surgery for Cancer Outcome
• Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.
• Anti-CEA CAR-T Cells to Treat Colorectal Liver Metastases
• Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
• PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer
• Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)
• Irinotecan Plus Anlotinib or Further in Combination With Piamprizumab for Second-line Treatment of mCRC
• Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer
• Testing Obeticholic Acid for Familial Adenomatous Polyposis
• Effects of Preoperative Correction of Anemia With Intravenously Iron in Colorectal Cancer Patients.
• Effects of Intravenous Administered Iron in Non-anemic Iron Deficient Patients With Colorectal Cancer
• BRAF V600E-mutant and MSI-H Metastatic Colorectal Cancer Study of Encorafenib Taken With Cetuximab Plus Pembrolizumab Compared to Pembrolizumab Alone
• Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
• NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer
• D,L-MEthadone and mFOLFOX6 in Treatment of Advanced Colorectal Cancer
• A Phase Ib/IIa Study of CR6086 in Combination With Balstilimab in pMMR-MSS Metastatic Colorectal Cancer Patients
• Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Positive Advanced Colorectal Cancer
• A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastric and Colorectal Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy
• Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC).
• Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1α True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine
• A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer
• mFOLFOXIRI Compared to mFOLFOX6 or CapeOx as Adjuvant Chemotherapy for Stage IIIB or IIIC Colorectal Cancer
• Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation
• NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer
• JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation
• Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer
• Effect of Jianpi Huatan Decoction on Advanced Colorectal Cancer
• Phase II Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Ovarian, Colorectal, or Appendiceal Cancer
• Perioperative Iron for Colorectal Cancer (PICoC Study)
• ibi308 Combined With Bevacizumab + XELOX Regimen in Advanced Colorectal Cancer
• A Study of ES104 in Patients With Metastatic Colorectal Cancer
• A Study of ALX148 With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer
• S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers
• SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer
• Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal Cancer
• Molecular Effects of Aspirin & Metformin on Colonic Epithelium
• Safety of Cetuximab and Trifluridin Tipiracil as the Third-line Therapy in the RASwt mCRC
• TES RCT Fleet Enema vs Oral Mechanical Bowel Prep
• Phase II Study of Tirelizumab Combined With Cetuximab and Irinotecan in the Treatment of Recurrent, Refractory mCRC
• A Study of a Personalized Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
• Pembrolizumab for Locally Advanced, Irresectable, Non-metastatic dMMR Colorectal Cancers
• A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer
• A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Colorectal Cancer
• The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation
• Atezolizumab With/Without IMM-101 in Patients With MSI-h/MMR-D Stage III Colorectal Cancer Ineligible for Oxaliplatin
• Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Patients With Colorectal Cancer
• Testing Obeticholic Acid (OCA) for Familial Adenomatous Polyposis (FAP)
• Phase II Study Comparing Conversion Rate to Surgery With Hepatic Arterial Infusion Chemotherapy to Systemic Chemotherapy in Patients With Non Resectable Liver-only Colorectal Metastases
• Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers
• Enhanced Monitoring for Better Recovery and Cancer Experience in Greater Manchester
• A Study to Evaluate Safety and Efficacy of BEY1107 in Combination With Capecitabine in Patients With Metastatic Colorectal Cancer
• Radioembolization in Elderly/ Fragile Patients With mCRC
• Magnetic Particle-ICG Lymph Node Mapping in Colorectal Cancer
• A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
• A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
• Study of αPD1-MSLN-CAR T Cells to Evaluate the Safety, Tolerability, and Effectiveness for Patients With MSLN-positive Advanced Solid Tumors
• Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer
• A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
• Brazilian Total Neoadjuvant Therapy Trial
• Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRC
• CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
• A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx
• A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)
• Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)
• Cryoablation Combined With Sintilimab Plus Regorafenib In Previously Treated Colorectal Cancer Liver Metastasis
• ASPIRED-XT: ASPirin Intervention for the REDuction of Colorectal Cancer Risk -EXTension
• Efficacy and Safety of SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies
• A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies
• DAILY: Vitamin D, Aspirin, ExercIse, Low Saturated Fat Foods StudY in Colorectal Cancer Patients With Minimal Residual Disease
• Anlotinib Combined With mXELIRI as Second-line Treatment of Advanced Colorectal Cancer
• PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer
• Temozolomide and Irinotecan in Patients With MGMT Silenced Colorectal Cancer After Adjuvant Chemotherapy
• A Phase II Study on Dose Optimization of Fruquintinib in Elderly mCRC Patients Refractory to Standard Treatment（DOFEMCRC）
• Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer
• FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer
• Fruquintinib Plus Capecitabine as Maintenance Treatment of RAS / BRAF Wild-type Metastatic Colorectal Cancer
• A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis
• Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)
• Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer
• Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRC
• Fruquintinib Combined With mFOLFOX6/FOLFIRI in First-line Treatment for Metastatic Colorectal Cancer
• A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.
• A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
• Phase 1b Study to Evaluate the Addition of a Pembrolizumab Treatment After Treatment With CYAD-101 With a FOLFOX Preconditioning in Metastatic Colorectal Cancer Patients
• Toripalimab Plus Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Advanced MSI-H or dMMR Colorectal Cancer
• The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment
• Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
• Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003
• A Phase II Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
• Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC
• The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE)
• Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in pMMR/MSS CRLM Patients
• Surufatinib Combine With Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal Cancer
• A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (Intrinsic)
• Tislelizumab Combined With Surufatinib and SBRT as Athird-line and Posterior Line Treatment in Patients With Oligometastatic CRC
• CTC vs Radiography as the Evidence of Recurrence in Colorectal Cancer Patients
• Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC
• A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)
• Efficacy of Mosapride on Recovery of Intestinal Motility After Elective Colorectal Cancer Surgery
• A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
• Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
• A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab in Participants With Advanced Solid Tumors
• mFOLFOX6+Bevacizumab+PD-1 Monoclonal Antibody in Local Advanced MSS CRC
• Study of ESG401 in Adults With Solid Tumors
• A Trial of Camrelizumab Combined With Microwave Ablation and Chemotherapy in the Treatment of Colorectal Cancer Liver Metastasis/Pulmonary Metastasis
• Evaluation of a Cosmetic Product to Preserve Skin Conditions When Using Anti-EGFR Cancer Therapies
• Evaluation of Treatment PERSOnalization Based on Its Therapeutic Monitoring in Patients With Metastatic Colorectal Cancer Treated With REgorafenib
• TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)
• Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer
• Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy
• Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer
• A Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Colorectal Cancer Unsuitable for Intravenous Chemotherapy
• A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC
• A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer
• A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations
• Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer
• A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
• Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
• Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy
• A Dose Escalation and Expansion Study of MVC-101 in Patients With Advanced Cancer
• Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC
• c-CetuIRI Versus Ersecond-line Irinotecan s-IRI-CetuIRI
• Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment
• Study of the Safety and Effectiveness of HIFU Combined With REGOTORI for Metastatic Colorectal Cancer
• VASCular Impact of Angiogenic Treatment in Patients With Advanced Colorectal Cancer
• Plasma Biomarker for Aflibercept in Advanced Colorectal Cancer
• Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer
• Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
• Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer
• PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence
• A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer Using ctDNA: Rapid 1 Trial
• mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases
• Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB
• Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)
• A Prospective Study Utilizing Circulating Cell Free DNA (cfDNA) Use in the Detection of RAS Mutations in Patients With Advanced Colorectal Cancer.
• Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
• Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
• Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study
• Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
• Raltitrexed in HIPEC
• SGM-101 in Colorectal Brain Metastases.
• Alpelisib and Capecitabine in Patients With PIK3CA Mutant mCRC Patients
• A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With BI 754091 to Patients With Advanced Solid Tumors Having the B7-H6 Marker
• A Phase lb/ll, Open Label, Single Arm Study With Olinvacimab and Capecitabine in mCRC Patients (OLCAP)
• Efficacy and Safety of Sintilimab Combined With Regorafenib and Cetuximab / Sintilimab Combined With Regorafenib in Posterior Line Therapy of Advanced Colorectal Cancer (Regosinti)
• Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer
• SGM-101 in Colorectal Lung Metastases
• Phase III Study of Trifluridine/Tipiracil in Combination With Bevacizumab vs Trifluridine/Tipiracil Single Agent in Patients With Refractory Metastatic Colorectal Cancer
• Second-line Surufatinib Combined With Chemotherapy in Advanced CRC
• Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer
• Efficacy and Safety of Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI Metastatic Colorectal Cancer
• Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders
• A Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma
• PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer
• Anastomotic Leakage and Value Of Indocyanine Green in Decreasing Leakage Rates
• TH1902 in Patients With Advanced Solid Tumors
• Combining Epigenetic And Immune Therapy to Beat Cancer.
• Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
• TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
• Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
• The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors
• Phase II Trial of Fruquintinib With Sintilimab in Treating Selected Refractory Metastatic Colorectal Cancer Patients
• 5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.
• Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases
• Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer
• A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma
• LYT-200 Alone and in Combination With Chemotherapy or Anti-PD-1 in Patients With Metastatic Solid Tumors
• A Study of SGN-STNV in Advanced Solid Tumors
• Study on the Correlation Between Gene Mutation and TCM Syndrome Types in Metastatic Colorectal Cancer
• An Open Label Study Evaluating the Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer.
• Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer
• Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC
• A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions
• A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
• Study to Assess the Safety and Efficacy of Intravenous Injection of the Imaging Agent 111In-IPN01087 in Patients With Locally Advanced or Metastatic Pancreatic or Colorectal Cancer.
• A Study to Test Different Doses of BI 1701963 in Combination With Irinotecan in People With Advanced Bowel Cancer With Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutation
• LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer
• Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):
• BRAF V600E-mutant Colorectal Cancer Study of Encorafenib Taken With Cetuximab Plus or Minus Chemotherapy (BREAKWATER)
• SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial
• Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease
• Difference of Surgical Site Infection Between Using Sodium Picosulfate Solution(PicosolutionⓇ) and Oral Sulfate Tablet(ORA·FANGⓇ) in Colorectal Cancer Surgery
• Intratumoral Influenza Vaccine for Early Colorectal Cancer
• Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
• Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer
• Nivolumab+Ipilimumab+RT in MSS mCRC
• Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients.
• Microwave Ablation Combined With Chemotherapy for Colorectal Liver Metastases： a Multicenter Cohort Study
• Avelumab Plus Cetuximab in Pre-treated RAS Wild Type Metastatic Colorectal Cancer
• AK104 in Locally Advanced MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer
• Hepatic Arterial Infusion Pump Chemotherapy Combined With Systemic Chemotherapy (PUMP-IT)
• A Phase I/II Study With BM7PE Immunotoxin in Colorectal Cancer Patients
• NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors
• A Clinical Study to Evaluate Efficacy and Safety of HLX10 Combined With HLX04 and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)
• Study to Evaluate the Safety of IMM-01 in Patients With Advanced Solid Tumours
• Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines
• The Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in MSS Oligometastatic Colorectal Cancer
• Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer
• Comparison of Methylprednisolone or Methotrexate in the Maintenance Treatment of Nasal Polyposis
• Effect of Vitamin d Deficiency in Chronic Rhinosinusitis With Nasal Polyposis
• QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer
• Conversion Therapy of RAS/BRAF Wild-Type Right-sided Colon Cancer Patients With Initially Unresectable Liver Metastases
• IV Ascorbic Acid in Peritoneal Metastatic Colorectal Cancer
• Effect of Transversus Abdominis Plane Block Combined With Dexmedetomidine Infusion on the Prognosis in Elderly Patients Undergoing Abdominal Surgery
• Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)
• AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients
• A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing Tumors
• Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer
• Cetuximab Re-challenge for Colorectal Cancer Liver Metastasis
• A Phase II Prospective Trial of mXELOXIRI Reintroduction for mCRC
• Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis
• MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)
• Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers
• A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
• A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer
• A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer
• Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer
• Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
• Fuzheng Yiliu-1010
• Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection
• Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer
• Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)
• Azithromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis
• Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer
• A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
• FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer
• Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
• Dupilumab Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis
• Study of Metronomic Capecitabine and Oxaliplatin Versus XELOX in Egyptian Metastatic Colorectal Cancer Patients
• Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer
• Study of ASN004 in Patients With Advanced Solid Tumors
• Effect of Hemp-CBD on Patients With CIPN
• TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.
• A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal Cancer
• A Clinical Study of Pyrotinib in Patients With HER2-positive Advanced Colorectal Cancer
• Efficacy of HIPEC in Patients With Colorectal Cancer at High Risk of Peritoneal Carcinomatosis
• To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of YYB101 With Irinotecan, Patients Who Are Metastatic or Recurrent Colorectal Cancer Patients
• Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer
• Axitinib Monotherapy With Early Dynamic Contrast Enhanced Ultrasound Monitoring in Chemorefractory Third Line Metastatic Colorectal Cancer
• mFOLFOXIRI Versus mFOLFOX6 as Adjuvant Chemotherapy for Locally Advanced Colorectal Cancer
• A Study of AL2846 Capsule Combined With Standard Chemotherapy Regimen in Subjects With Advanced Colorectal Cancer
• PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
• The Safety and Tolerability of PD-L1 Monoclonal Antibody Plus Lenalidomide in The Treatment of Colorectal Cancer
• A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer
• A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Patients With Metastatic Colorectal Cancer
• Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer
• Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer
• Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma
• PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer
• Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.
• A Trial of SHR-1210 in Combination With AIN457 in Patients With MSS CRC（SHR-1210-AIN457）
• Two Low Volume Regimens for Colorectal Cancer Screening Colonoscopy
• Niclosamide for Familial Adenomatous Polyposis
• Efficacy of Perioperative Duloxetine as a Part of Multimodal Analgesia in Laparoscopic Colorectal Cancer Surgery
• TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer
• A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer
• Mechanical Bowel Preparation and Oral Antibiotics Versus Mechanical Bowel Preparation Only Prior Rectal Surgery
• Codman Catheter/Synchromed Pump Hepatic Artery Chemotherapy for Unresectable Colorectal Metastases/Intrahepatic Cholangiocarcinoma
• Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CR)
• Study of Oral Metronidazole on Postoperative Chemotherapy in Colorectal Cancer
• Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate
• Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal Cancer
• Pedaling at a Low-Moderate Intensity During Chemotherapy Administration
• Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment
• A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer
• Investigation of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI
• Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer
• A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
• A Study of Cetuximab Plus Raltitrexed for Maintenance Treatment in Advanced Colorectal Cancer
• Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR+ Cancers by Positron Emission Tomography (PET)
• QL1203 In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy and Safety
• Trial of eRapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance
• Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer
• A Study of Pyrotinib Combined With Capecitabine for Metastatic HER-2 Positive Colorectal Cancer
• Re-challenge of Anti-EGFR for Patients With RAS/BRAF Wild-type Metastatic CRC
• Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
• PRevention Using EPA Against coloREctal Cancer
• Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer
• Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal Cancer
• Clinical Trial of Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer
• Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer
• A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Metastatic Colorectal Cancer
• Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal Cancer
• PRevention Using EPA Against coloREctal Cancer
• FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer
• LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment Efficacy
• TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer
• VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)
• A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation
• Dasatinib in Preventing Oxaliplatin-Induced Peripheral Neuropathy in Patients With Colorectal Cancer Receiving FOLFOX and Bevacizumab
• Elucidation of the Mechanisms and Effects of Certain Anesthetic Interventions on Digestive Cancer Patients Subjected to Surgery
• mXELOXIRI Combined With Molecular Targeted Drug in mCRC
• Effect of Atorvastatin on 5-Fluorouracil Induced Mucositis
• Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC
• Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer
• Probiotics Combined With Standard Chemotherapy Plus Targeted Therapy in Patients With Metastatic Colorectal Cancer
• Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)
• Modelle 001, TS-inhibition in Colorectal Liver Metastases Comparing Arfolitixorin and Calciumfolinate
• Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer
• A Study for PD-1 Antibody JS001 in MSI-H Advanced or Recurrent Colorectal Cancer
• Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
• Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer
• Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer
• TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study
• Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
• Impact of an Optimised Monitored Anesthesia on the Patients' Recovery After Cytoreduction Surgery Plus HIPEC
• CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC
• Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations
• Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
• Sirolimus for Cowden Syndrome With Colon Polyposis
• Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients
• A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors
• Phase 1b/2 Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer
• Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients
• COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC
• Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal Cancer
• Local Immunomodulation After Radiofrequency of Unresectable Colorectal Liver Metastases
• GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
• Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer
• A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
• Encorafenib, Binimetinib, and Nivolumab in Treating Patients With Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer
• A Study of SGN-CD228A in Advanced Solid Tumors
• FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC
• Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy in Adjuvant Colorectal Cancer
• High Dose Vitamin C Combined With Metformin in the Treatment of Malignant Tumors
• LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)
• Regorafenib and Nivolumab in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal Cancer
• Chemotherapy w/wo WeiLeShu in Metastatic Colorectal Cancer
• Screening for Colorectal Cancer in Average and High Risk Population
• Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
• Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study
• Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer
• A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
• Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
• First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation
• Study of Elunate® (Fruquintinib) in Chinese Patients With Advanced CRC
• Anti-PD-1 +/- RT for MSI-H Solid Tumors
• Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies
• A Trial of CXD101 in Combination With Nivolumab in Patients With Metastatic Microsatellite-Stable Colorectal Cancer
• Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
• Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor
• Window of Opportunity Study in Colorectal Cancer
• Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer
• Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors
• Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy
• Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer
• A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer
• Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer
• Bioequivalence Study of Trifluridine and Tipiracil Tablets in Colorectal Cancer Patients
• Assessment of Direct Biomarkers of Aspirin Action to Develop a Precision Chemoprevention Therapy of Colorectal Cancer
• A Safety Study of SGN-CD47M in Patients With Solid Tumors
• Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer
• Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
• JS001 Combined With Regorafenib in Patients With Advanced Colorectal Cancer
• Re-challenge Therapy With Chemotherapy & Panitumumab in Metastatic Colorectal Cancer Patients Treated With an Anti-EGFR
• Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
• A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
• Phase II Study of Toripalimab Plus Stereotactic Body Radiotherapy in Colorectal Cancer Patients With Oligometastasis
• Toripalimab With or Without Celecoxib as Neoadjuvant Therapy in Resectable dMMR/MSI-H Colorectal Cancer
• Mebendazole as Adjuvant Treatment for Colon Cancer
• Colorectal Metastasis Prevention International Trial 2
• Prophylactic Surgery Plus HIPEC With CO2 in Patients Affected by Colorectal Carcinoma. CHECK Study.
• Camrelizumab(SHR-1210) Combined With Apatinib in the Treatment of Advanced Metastatic Colorectal Cancer
• Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC)
• Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Colorectal Cancer
• Zinc Supplement in Regorafenib Treated mCRC Patient
• Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
• Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer
• Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer
• A Study of LUT014 in Patients With Metastatic Colorectal Cancer With EGFR Inhibitor Induced Acneiform Lesions
• Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
• Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
• Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.
• iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer
• A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma
• Prophylatic Effect Preoperative Antibiotics With Mechanical Bowel Preparation in SSIs
• Immunotherapy In Locally Advanced Rectal Cancer
• Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors
• Pembrolizumab After Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and Who Are Undergoing Liver Surgery
• Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer
• Pemetrexed and S-1 in Combination With Bevacizumab in Refractory Colorectal Cancer
• Pyrotinib in Combination With Trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.
• FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
• A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)
• NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer
• Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE)
• Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients
• TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
• Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation
• Quality of Life in Elderly Patients With Metastatic Colorectal Cancer Receiving First-line Therapy Based on Simplified Geriatric Parameters
• Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia
• A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer
• Effect of Adding Simethicone to Split-dose Polyethylene Glycol for Bowel Preparation in a Screening Colonoscopy Setting
• RALOX or CAPOX + Bevacizumab in the First-line Treatment of Advanced CRC(ROCB Study)
• A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors
• Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis
• Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
• Improving Outcome of Selected Patients With Non-resectable Hepatic Metastases From Colo-rectal Cancer With Liver Transplantation
• Analgesia of Erector Spinae Plane Block Versus Quadratus Lumborum Block
• Cd133+ Cell Infusion in Patients With Colorectal Liver Metastases.
• Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases
• Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers
• Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer
• Study for Evaluation of GM102 Anti-tumoral Activity in Colorectal Cancers
• Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
• Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
• Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer
• Evaluation of the Efficacy and the Safety of FOLFIRINOX3 Bevacizumab Treatment in Patients With Colorectal Cancer (FOLFIRINOX 3)
• Intraperitoneal and System Chemotherapy Versus XELOX as First-line Chemotherapy for mCRC
• BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRC
• Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
• Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or Lymphoma
• Targeted Polymeric Nanoparticles Loaded With Cetuximab and Decorated With Somatostatin Analogue to Colon Cancer
• Imaging With [89Zr]Panitumumab-PET/MRI in Patients With Newly Diagnosed Colorectal Cancer
• Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
• Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal
• A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer
• IMPROVE Intervention Trial Implementing Non-invasive Circulating Tumor DNA Analysis to Optimize the Operative and Postoperative Treatment for Patients With Colorectal Cancer
• Adjuvant Chemotherapy in Clinical Local Advanced CRC Following Preoperational Therapies and pT0-3N0M0 Diagnosis
• Biomarkers for Apatinib and Bevacizumab in Second-line Therapy for Colorectal Cancer(BABST-C)
• Effect of Probiotics Supplementation on the Side Effects of Radiation Therapy Among Colorectal Cancer Patients
• A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer
• An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors
• A Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors
• Study of Radspherin® in Colorectal Carcinoma Subjects With Peritoneal Carcinomatosis Treated With HIPEC
• Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT)
• Vactosertib in Combination With Pembrolizumab in Metastatic Colorectal or Gastric Cancer
• [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)
• Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors.
• Intraoperative TAP Block With Bupivacaine/Dexamethasone Against Liposomal Bupivacaine (Exparel®)
• FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients
• A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies
• Sym004 Versus TAS-102 in Patients With mCRC
• Strengthening the Spleen and Reducing Phlegm Method in Improving Radical Resection Rate of Colorectal Cancer
• Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type
• Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer
• The Efficacy of Bevacizumab Combined With m-FOLFOXIRI in Borderline Resectable Colorectal Liver Metastases
• Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer
• Probiotics as Adjuvant Therapy in the Treatment of Metastatic Colorectal Cancer
• Influence of Opioid Analgesia on Circulating Tumor Cells in Laparoscopic Colorectal Cancer Surgery
• Influence of Opioid Analgesia on Circulating Tumor Cells in Open Colorectal Cancer Surgery
• Multi-modality Imaging in Peritoneal Carcinomatosis of Colorectal Origin
• Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab
• Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors
• A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma
• Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer
• alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
• A Study to Evaluate the Effect of ACT-774312 in Subjects With Bilateral Nasal Polyposis
• Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic Colorectal Cancer.
• PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
• 9-ING-41 in Patients With Advanced Cancers
• FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM
• Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy
• Dabrafenib + Trametinib + PDR001 In Colorectal Cancer
• OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer
• Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer
• Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer
• Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer
• Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M)
• A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
• A Study of Guselkumab in Participants With Familial Adenomatous Polyposis
• Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer
• SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer
• Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer
• PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer
• Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided,
• Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)
• A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
• A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies
• Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients
• First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors
• Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma
• Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer
• Evaluation of the Efficacy and Safety of Single Dose Tranexamic Acid in Reducing Blood Loss During Colorectal Cancer Surgery
• Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
• Chemotherapy and/or Metastasectomy in Treating Patients With Metastatic Colorectal Adenocarcinoma With Lung Metastases
• A Study of RGX-202-01 as a Single Agent and as Combination Therapy in Patients With Advanced Gastrointestinal Malignancies
• Study to Evaluate Safety & Tolerability of AGI-134 in Solid Tumour
• Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer
• Recombinant Human Endostatin in Combination With XELOX Therapy in Patient With Advanced Colorectal Cancer.
• Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer
• Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer
• Efficacy of Preoperative Intravenous Iron in Anaemic Colorectal Cancer Surgical Patients
• Total Neoadjuvant Treatment Without Surgery For Locally Advanced Rectal Cancer
• Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).
• Prospective Study on the Efficacy and Safety of 2 Week or 3 Week Xelox Regimen for Adjuvant Chemotherapy in CRC
• QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
• Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer
• A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)
• Sym004 Versus Futuximab or Modotuximab in Patients With mCRC
• A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
• A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC
• Safety and Efficacy of Anlotinib in Combination With Irinotecan in Patients With Pretreated Advanced Colorectal Cancer
• Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer
• Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
• Oligometastases of the LIVer Treated With Chemotherapy With ou Without Extracranial Stereotactic Body Radiation Therapy in Patients With Colorectal Cancer
• Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer
• A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
• Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
• Cetuximab Therapy for Third Line Rechallenge in Metastatic Colorectal Cancer
• A Phase III Clinical Study of Napabucasin (GB201) Plus FOLFIRI in Adult Patients With Metastatic Colorectal Cancer
• RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients
• Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status
• TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated mCRC
• A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC
• XELOX+Bevacizumab and XELIRI + Bevacizumab Alternative Regimen as First-line Treatment for Advanced Colorectal Cancer
• XELOX and XELIRI Alternative Regimen as First-line Treatment for Advanced Colorectal Cancer
• Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer
• Systemic Chemotherapy Plus HAI(FUDR）vs Systemic Chemotherapy Alone For CRCLM
• Liver Transplantation Compared to Chemotherapy in Patients With ColoRectal Cancer
• A Study of Systemic Chemotherapy With CPT-11 Plus HAI (FUDR+L-OHP) in Patients With Initially Unresectable CRCLM
• Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM
• A Preliminary Clinical Study on the Pharmacokinetics and Safety of CDP1 in Patients With Advanced CRC or HNSCC
• Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
• Rechallenge of Prior Regimen in Third or Later-line Chemotherapy in Metastatic Colorectal Cancer
• Ultrasound-enhanced Delivery of Chemotherapy to Patients With Liver Metastasis From Breast- and Colorectal Cancer
• Study of NEO-201 in Solid Tumors Expansion Cohorts
• A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
• Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer
• Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)
• Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer
• Association of Capecitabine Pharmacokinetics and Toxicity With Aging
• Targeted Delivery of Chemotherapy With Ultrasound and Microbublles
• Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status
• A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy
• CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
• Skin Toxicity in Patients With Metastatic Colorectal Cancer Treated With Anti-EGFR and Chemotherapy (DERMIA)
• SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients
• Palbociclib and Cetuximab in Metastatic Colorectal Cancer
• ABI-009 (Nab-rapamycin) in Combination With FOLFOX and Bevacizumab as First-line Therapy in Patients With Advanced or Metastatic Colorectal Cancer
• M7824 in Consensus Molecular Subtype 4, Treatment-Refractory Metastatic Colorectal Cancer
• A Study of NKTR-262 in Combination With Bempegaldesleukin (NKTR-214) and With Bempegaldesleukin Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies
• Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer
• A Safety Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment
• Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer
• Clinical Trial of PM60184 in Advanced Colorectal Cancer After Standard Treatment
• Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial
• Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
• Study of Trastuzumab-emtansine in Patients With HER2-positive Metastatic Colorectal Cancer Progressing After Trastuzumab and Lapatinib.
• An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread
• Clinical Study of Apatinib Combined With Second - Line Chemotherapy for Metastatic Colorectal Cancer
• Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver
• Apatinib in the Treatment of Metastatic Colorectal Cancer
• Conversion From Unresectable To Resectable Metastatic Colorectal Cancer.
• HIPEC and Systemic Chemotherapy in Unresectable Peritoneal Metastases From Colorectal Cancer
• Study of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer
• Pembrolizumab, Capecitabine, and Bevacizumab in Treating Patients With Microsatellite Stable Colorectal Cancer That Is Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
• A Clinical Trial to Determine the Therapeutic Efficacy and Safety Between Cetuximab® (Produced by CinnaGen) and FOLFIRI Compared With Erbitux® (Cetuximab, Produced by Merck Company) and FOLFIRI for RAS Wild-type Metastatic Colorectal Cancer Patien
• METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin
• The Clinical Application of 68Ga Labeled ssDNA Aptamer Sgc8 in Healthy Volunteers and Colorectal Patients
• DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)
• Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer
• Apatinib Treatment as the Neoadjuvant Therapy in Advanced Colorectal Cancer
• An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread
• Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma
• Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651)
• TAS102 in Combination With NAL-IRI in Advanced GI Cancers
• A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab
• Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver
• mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal Cancer
• PETACC-8 miR-31-3p and miR-31-5p Ancillary Study
• Interest of iRECIST Evaluation for DCR for Evaluation of Patients With Deficient MMR and /or MSI Metastatic Colorectal Cancer Treated With Nivolumab and Ipilimumab
• A Study of Apatinib in Combination With Raltitrexed Treatment in Patients With Advanced Colorectal Cancer
• Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal Cancer
• Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer
• Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers
• A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
• High-dose FOLFIRI in Advanced Colorectal Cancer Patients With Wild-type UGT1A1*6 and *28
• Aspirin in Colorectal Cancer Liver Metastases
• Mometasone vs Budesonide in CRS With Polyposis
• FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
• Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery
• A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
• Anti-EGFR Therapy Rechallenge in Combination With Chemotherapy in Patients With Advanced Colorectal Cancer
• Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer
• A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic).
• Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy
• A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC
• 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab
• Dolcanatide in Preventing Colorectal Cancer in Healthy Volunteers
• Comparative Effectiveness of Split-Dose Colonoscopy Bowel Preparation Regimens
• Oligometastases of the LIVer Treated With Chemotherapy With ou Without Extracranial Stereotactic Body Radiation Therapy in Patients With Colorectal Cancer
• Safety, Tolerability and Pharmacokinetics of Oral Tablet of Irinotecan in Adult Patients With Solid Tumors
• Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignancies
• Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer
• Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancer
• MYPHISMO: MYB and PD-1 Immunotherapies Against Multiple Oncologies Trial
• A Research of Berberine Hydrochloride to Prevent Colorectal Adenomas in Patients With Previous Colorectal Cancer
• Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients
• NEOadjuvant Chemotherapy Only Compared With Standard Treatment for Locally Advanced Rectal Cancer
• Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an
• Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Standard Chemotherapies
• Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC
• The Effect of Ketamine on Immune Function and Prognosis in Patients Undergoing Colorectal Cancer Resection
• The Correlation of Surgical Colorectal Cancer Specimen Pathology With the Fluorescence of Photodynamic Diagnostics
• Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C)
• Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation
• A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors
• Trial of Aflibercept Monotherapy With DCE-US in Chemorefractory Metastatic Colorectal Cancer
• Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer
• A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors
• Combination of TATE and PD-1 Inhibitor in Liver Cancer
• A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer
• Lidocaine for Oxaliplatin-induced Neuropathy
• A Study of SC-007 in Subjects With Advanced Cancer
• Assessing Safety of NIPOX in Peritoneal Carcinomatosis of CRC
• Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer
• First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS
• QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
• Apatinib for Resectable Colorectal Cancer
• Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance
• Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer
• Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal Cancer
• Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer
• Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC
• PEN-866 in Patients With Advanced Solid Malignancies
• A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer
• Phase I/II Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer
• Clinical Study of Apatinib and 5-Fu Combination Regimen to Treat Advanced Colorectal Cancer Patients
• CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer
• A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer
• Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer
• Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRC
• Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers
• Safety and Efficacy Study of Chemotherapy Plus Apatinib as Second-line Therapy in Metastatic Colorectal Cancer
• Study of TCM Syndrome of Hepatocellular Carcinoma and Colorectal Cancer Based on System Science
• Low-Dose Ibuprofen in Improving Cognitive Impairment in Patients With Cancer
• Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer
• Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System
• TSA-DC Vaccine in Treating Patients With Gastrointestinal Solid Tumor
• A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors
• Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer
• PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer
• Irinotecan-Eluting Bead (DEBIRI) for Patients With Liver Metastases From Colorectal Cancer
• Avelumab and Cetuximab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer - The Phase II AVETUX-CRC Trial.
• QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC
• Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer
• Panitumumab Skin Toxicity Prevention Trial
• Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network
• First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide
• Biological-guided Metronomic Chemotherapy as Maintenance Strategy in Metastatic Colorectal Cancer
• Dose Escalation Study of Lithium With Oxaliplatin and Capecitabine in Advanced Oesophago-Gastric or Colorectal Cancer
• Avelumab Plus Autologous Dendritic Cell Vaccine in Pre-treated Metastatic Colorectal Cancer Patients
• Avelumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer
• The p53 Colorectal Cancer Trial
• High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies
• A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer
• FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status
• Consolidative Radiotherapy Plus Maintenance Chemotherapy for Metastatic Colorectal Cancer
• Consolidative Radiotherapy for Colorectal Cancer Liver Metastases Receiving Surgery or Radiofrequency Ablation
• Study of Apatinib and Capecitabine Combination to Maintain Treating Metastatic Colorectal Cancer
• The Efficacy of Silymarin as Adjuvant Therapy on Colorectal Cancer Patients Undergoing FOLFIRI Treatment
• A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
• Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM
• Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer
• A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer
• Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels
• Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer
• Synergism of Immunomodulation and Tumor Ablation
• Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC
• A CR-UK Phase I Trial of LY3143921
• Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer
• Sirolimus and Familial Adenomatous Polyposis (FAP)
• Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer (NeoART-V)
• Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer
• Pemetrexed Plus Tarceva as Salvage Treatment in EGFR Overexpressed Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy
• A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
• Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer
• Comparing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C Versus Melphalan for Colorectal Peritoneal Carcinomatosis
• Investigating the Use of Fluorescent Lectins to Identify Dysplasia and Cancer During Endoscopy and Surgery
• Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome
• Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver
• Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis After Laparoscopic Surgery for Colorectal Cancer.
• APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors
• Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004
• A Randomized, 2x2 Factorial Design Biomarker Prevention Trial of Low-dose Aspirin and Metformin in Stage I-III Colorectal Cancer Patients.
• Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer
• Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery
• Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
• A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer
• A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer
• A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer
• Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis
• An Evaluation of Tilmanocept by IV Injection Using SPECT/CT vs PET Imaging in Subjects With Liver Metastases.
• Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy
• Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study
• Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers
• Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer
• Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer
• A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors
• Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer
• Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer
• Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients
• Cetuximab Monotherapy Maintenance Treatment in mCRC
• Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas
• Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013)
• Phase II Trial to Assess FOLFIRI+Aflibercept Efficacy in Patients With Oxaliplatin-pretreated Metastatic Colorectal Cancer With or Without ACE Polymorphisms
• Long Term Effect of Oxaliplatin Treatment in Cancer Survivors
• Vitamin C Intravenously With Chemotherapy in Advanced Colorectal Cancer
• Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma
• Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients
• Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Versus no HIPEC in Locally Advanced Colorectal Cancer (APEC Study)
• A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
• Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer
• Study of ASN003 in Subjects With Advanced Solid Tumors
• A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy
• Equivalence of Monitoring by a Nurse Practitioner for Patients With Digestive Cancer
• An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
• Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer
• A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors
• Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
• Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk
• Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC
• Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer
• FOLFIRI Versus Irinotecan as Second-line Treatment in Metastatic Colorectal Cancer Patients
• Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab
• Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer
• Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With
• Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.
• A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion
• Aprepitant Without Steroid in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal Cancer
• Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer
• Study of I Line FOLFOX + Panitumumab vs 5FU + Panitumumab in RAS and BRAF WT Metastatic Colorectal Cancer Elderly Patients
• Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
• A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)
• Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
• Metronomic Versus Conventional Chemotherapy in as Maintenance Treatment in mCRC
• A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
• Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
• Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
• Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer
• Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer
• Donafenib for Previously Treated Metastatic Colorectal Cancer
• SOX Versus XELOX for Patients With Peritoneal Metastasis of Colorectal Cancer
• Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of Simmitecan Monotherapy and Combination in Patients With Advanced Solid Tumors
• Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome
• CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
• A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer
• A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC
• A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
• Special Combination of BBI608 and Pembrolizumab
• Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer
• TAS-OX for Refractory Metastatic Colon Cancer
• De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer
• Cohort Study to Assess Impact of Chemotherapy Plus Bevacizumab on Health Related Quality of Life in First Line Metastatic Colorectal Cancer
• Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer
• PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer
• Study Comparing Different Dose Approaches of Induction Treatment of Regorafenib in MCRC
• Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI
• A Real World Study to Evaluate Effectiveness of Avastin (Bevacizumab) for First Line Treatment of Patients With Metastatic Colorectal Cancer and Known KRAS Status
• Radical Colorectal Resection and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Colorectal Cancer
• Clinical Study of Apatinib and XELOX Combination Regimen to Treat Colorectal Cancer Patients
• LEAC-102 for Advanced Colorectal Cancer
• Biweekly Versus Triweekly Raltitrexed With Oxaliplatin (With or Without Bevacizumab) in First-line Metastatic Colorectal Cancer
• Study of Azacitidine and Durvalumab in Advanced Solid Tumors
• Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours
• The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib
• Huaier Granule As Adjuvant Therapy for Colorectal Cancer After Radical Surgery
• A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)
• Anesthesia and Postoperative Outcome in Colorectal Cancer Patients
• Adjuvant Chemotherapy Combined With Huaier Granule for Treating High-risk Stage II, Stage III Colorectal Cancer
• Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer
• Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Chronic Rhinosinusitis With Nasal Polyposis
• Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]
• Prophylactic or Preemptive Entecavir in Patients With Colorectal Cancer Who Are Inactive Hepatitis B Carriers
• Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers
• Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal Cancer
• Perioperative Systemic Therapy in Patients Undergoing Surgery With HIPEC for Colon Cancer With Peritoneal Metastases: the CAIRO6 Study.
• CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors
• Tremelimumab (Anti-CTLA-4) Plus MEDI4736 (Anti-PD-L1) in Resectable Colorectal Cancer Liver Metastases
• A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer
• Application of Two Anti-angiogenesis Drugs Combined With Chemotherapy in Advanced Colorectal Cancer Under the Background of Precision Medical
• Insulin Therapy Reduce Post-Operative Inflammatory Response After Curative Colorectal Cancer Resection: Randomization Controlled Trial
• A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents
• A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy
• A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies
• Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by Surgery
• Study to Evaluate Multiple Doses in Patients With Nasal Polyposis
• First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors
• A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer.
• Pemetrexed and Erlotinib for Metastatic Colorectal Cancer
• Study of TKI 258 in Combination With Xeloda and Oxaliplatin in Advanced Colorectal and Gastric Cancer
• VXM01 Phase I Study in Patients With Metastatic Colorectal Cancer With Liver Metastasis
• Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer
• E. Coli Nissle in Oncology
• Side Effects to FOLFOXIRI + Tocotrienol/Placebo as First Line Treatment of Metastatic Colorectal Cancer
• Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors
• Evaluation of Treatment Response With CHOI and RECIST Criteria and CT Texture Analysis in Patients With Metastatic Colorectal Cancer Treated With Regorafenib
• Neoadjuvant Triplet Chemotherapy Regimen in Patients With Resectable Colorectal Cancer
• MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
• Stivarga Real Life Evidence in Hungary
• Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers
• Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer
• Phase II Study of Perindopril and Regorafenib in mCRC
• TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors
• Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
• Adjuvant Low Dose Aspirin in Colorectal Cancer
• Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
• A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer
• A Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer
• A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
• Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer
• Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatment
• Soluble Vascular Endothelial Growth Factor Receptor 2 as Predictor of Benefit From Bevacizumab Beyond Progression in Metastatic Colorectal Cancer
• Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer
• PET/CT Scan as a Tool to Rationalize the Treatment of Patients With Advanced ColoRectal Cancer Undergoing First-line Medical Treatment
• Combined Use of Raltitrexed and S-1 as Treatment for Patients With Metastasizing Colorectal Cancer
• A Study of Type-1 Polarized Dendritic Cell (αDC1) Vaccine in Combination With Tumor-Selective Chemokine Modulation (Interferon-α2b, Rintatolimod, and Celecoxib) in Subjects With Chemo-Refractory Metastatic Colorectal Cancer
• Clinical Trial to Evaluate Safety and Efficacy of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) With Mitomycin C Used During Surgery for Treatment of Locally Advanced Colorectal Carcinoma
• Effect of Adjunctive Metformin on Recurrence of Non-DM Colorectal Cancer Stage II High-risk/ III Colorectal Cancer
• A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers
• A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer
• Observation of Patients With Metastatic Colorectal Cancer Starting Chemotherapy Combined With Bevacizumab (Avastin)
• Aspirin for Prevention of Postsurgical Recurrence and Metastasis in Asian Colorectal Cancer Patients: a Multi-center Randomized Trial
• Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer
• Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
• Histopathological Response to FOLFOXIRI + Bevacizumab in Peritoneal Metastasis From Colorectal Cancer
• Pemetrexed Alone as Salvage Treatment in Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy: A Phase II Single Arm Prospective Study
• ImmunoTEP With 68-Ga in Metastatic Colo Rectal Cancer
• A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours
• Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
• A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum
• A Study of Capecitabine (Xeloda) in the Adjuvant Treatment of Participants With Resected Colon Cancer
• Efficacy of Ginseng for Patients on Regorafenib
• A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
• A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Adjuvant HIPEC to Prevent Colorectal Peritoneal Metastases in High-risk Patients
• Maintenance Treatment With Capecitabine Metronomic Chemotherapy and Chinese Traditional Medicine in Metastatic Colorectal Cancer
• TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors
• Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer
• Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
• Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients
• A Study of Capecitabine (Xeloda) in Patients With Metastatic Colorectal Cancer
• Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)
• The Efficacy of MEDIHONEY® for Chronic Rhinosinusitis With Nasal Polyposis After Functional Endoscopic Sinus Surgery
• Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer
• Oxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases
• Effect of Simethicone on Bowel Preparation for Colonoscopy
• Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib
• Abscopal Effect for Metastatic Colorectal Cancer
• Alternating Systemic and Hepatic Artery Infusion Therapy As Adjuvant Treatment After Resection of Liver Metastases From Colorectal Cancer
• Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm
• Efficacy and Tolerability of Suprep With and Without Simethicone for Routine Colonoscopy for Colorectal Cancer Screening
• Drug Trial to Investigate the Safety and Efficacy of Niclosamide Tablets in Patients With Metastases of a Colorectal Cancer Progressing After Therapy
• Effect of G17DT in Patients With Stage II/III Colorectal Cancer
• A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab
• A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer
• Does Caffeine Reduce Postoperative Bowel Paralysis After Elective Colectomy?
• MEK and MET Inhibition in Colorectal Cancer
• Acupuncture for Postoperative Nausea and Vomiting in Patients Undergoing Colorectal Surgery
• FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer
• Trial of Antigen Pulsed Dendritic Cells (APDC) in Metastatic Colorectal Cancer
• Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer
• Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases
• Donafenib Monotherapy for Previously Treated Metastatic Colorectal Cancer
• Erbitux MEtastatic Colorectal Cancer Strategy Study
• Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Ca
• Optimization of the Bowel Preparation Regimen for the PillCam® COLON 2 Capsule Endoscopy Procedure
• Panitumumab-based Maintenance in Patients With RAS Wild-type, Metastatic Colorectal Cancer (Valentino)
• Intravenous Ferric Carboxymaltose vs. Oral Iron Substitution in Patients With Metastatic Colorectal Cancer (CRC) and Iron Deficiency Anemia: a Randomized Multicenter Treatment Optimization Study.
• Performance of NER1008 Enema Compared With Fleet® Enema in Bowel Cleansing
• Regorafenib in Metastatic Colorectal Cancer
• Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
• A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors
• Compare Efficacy and Safety of Raltitrexed-based and 5fu-based Neoadjuvant Chemotherapy for Colorectal Liver Metastasis
• A Phase Ib Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal Cancer
• Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer
• Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
• Avastin/FOLFIRI in Combination With Curcumin in Colorectal Cancer Patients With Unresectable Metastasis
• Safety Study of AMG 228 to Treat Solid Tumors
• Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer
• Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients
• Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX
• Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
• Efficacy and Safety of Oxaliplatin Combined With Capecitabine as Neoadjuvant Chemotherapy for Locally Advanced Colon Cancer Patients
• DC-CIK Immunotherapy Plus Chemotherapy vs Chemotherapy Alone in the Adjuvant Treatment of Stage III Colorectal Cancer
• Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients
• Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer
• Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC)
• A Multi-center Randomized Controlled Trial of Intraportal Chemotherapy Combined With Adjuvant Chemotherapy (mFOLFOX6) for Stage II and III Colon Cancer
• A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer
• A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer
• Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis
• An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Ca
• Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC
• ASPirin Intervention for the REDuction of Colorectal Cancer Risk
• Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer
• Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma（FACT）
• INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
• Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer
• Aflibercept +/- LV5FU2 in First Line of Non-resectalbe Metastatic Colorectal Cancers
• Dose Finding Study in Colorectal Cancer Patients Receiving 5-FU-based Chemotherapy to Assess the Efficacy of Elsiglutide in the Prevention of Chemotherapy Induced Diarrhea (CID)
• Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients
• Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer
• Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
• A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
• Colectomy in Patients With Asymptomatic and Unresectable Stage IV Colon Cancer
• Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors' Adjusted Version
• FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-type
• Assessment of Physical Activity During Therapy With Regorafenib for Metastatic Colorectal Cancer
• Hepatic Arterial Infusion With FOLFOX Alone or in Combination With IV Chemotherapy in Colon Cancer With Liver Metastasis
• Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC
• Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Carcinoma
• A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
• Study of Anlotinib in Patients With Metastatic Colorectal Cancer（mCRC）(ALTER0703)
• Study to Evaluate Oxygen Monitoring at Different Stages of Neuromuscular Blockade in Colorectal Surgery
• A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
• Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer
• Low-dose Capecitabine Adjuvant Chemotherapy for Elderly Patients With Stage II/III Colorectal Cancer
• Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study
• Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer
• Phase I:Decitabine by Hepatic Arterial Infusion(HAI) in Unresectable Liver Metastases Colorectal Cancer (CRC)
• A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients （FRESCO)
• Regorafenib in Metastatic Colorectal Cancer : a Cohort Study in the Real-life Setting
• Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects
• Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer
• Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer
• Pretargeted Radioimmunotherapy in Metastatic Colorectal Cancer
• AMP-224, a PD-1 Inhibitor, With Stereotactic Body Radiation Therapy in Metastatic Colorectal Cancer
• Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET).
• Effect of Oral Administration of Methylene Blue MMX Tablets on Double Stranded DNA
• Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
• A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)
• A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Outcomes?
• Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer
• Safety of Orectalip® (Oxaliplatin) as Adjuvant Treatment for High-risk Stage-Ⅱ Colorectal Cancer
• Pilot Trial of EGF Ointment for the Patients With EGFR-i Related Skin Side Effects
• Low Dose Metronomic Poly-chemotherapy for Metastatic CRC
• Cytokine-induced Killer Cell Immunotherapy for Surgical Resected Stage III Colorectal Cancer Patients After Chemotherapy
• Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations
• Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer
• Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus MOVIPREP® Using 2-Day Split-Dosing and 1-Day Morning Split-Dosing Regimen in Adults.
• Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus a Sodium Picosulfate and Magnesium Salt Solution Using Day Before-Only Dosing Regimen in Adults.
• Maintenance Bevacizumab Only or Bevacizumab Plus Metronomic Chemotherapy in Advanced Colorectal Cancer
• The Benefits of Deep Neuromuscular Block and Sugammadex in Laparoscopic Colorectal Surgery
• A Phase 2 Study of Pembrolizumab (MK-3475) in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer
• Prospective Analysis of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated With Bevacizumab Combined With FOLFIRI as the First-line Setting
• Observational Study to Evaluate the Use of Targeted Therapies in Metastatic Colorectal Cancer
• Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus Trisulfate Solution Using 2-Day Split-Dosing Regimen in Adults
• Effect of GM1 in Prevention of Oxaliplatin Induced Neurotoxicity in Stage II/III Colorectal Cancer
• A Randomized Prospective Trial Comparing Low-volume Bowel Preparation Methods
• To Determine the MTD and to Evaluate the Safety, Efficacy and PK Profiles of TSB-9-W1 in Pre-treated Patients With mCRC.
• Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma
• A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC
• Modufolin (Arfolitixorin) in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer
• Trial Comparing Ferric(III)Carboxymaltose Infusion With Oral Iron Suppletion as Treatment of Anaemia
• Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer
• CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
• Acetic Acid Colonoscopy Enhancement Study
• Adjuvant HIPEC in High Risk Colon Cancer
• Lapatinib Plus Trametinib in KRAS Mutant NSCLC
• Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer
• Bevacizumab-containing Regimen for Metastatic Colorectal Cancer Failed to Cytotoxic Treatment
• Immunotoxin in Peritoneal Carcinomatosis- ImmunoPeCa Trial
• Trial of FOLF(HA)Iri With Cetuximab in mCRC
• Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).
• Pain Relief After Colorectal Surgery: Spinal Combined With Painbuster® vs Painbuster® Alone.
• Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy
• Phase II-b Randomized Clinical Trial of Cabazitaxel in Metastatic Colorectal Cancer Resistant to Standard Treatment
• Adoptive Cell Therapy Plus Chemotherapy and Radiation After Surgery in Treating Patients With Colorectal Cancer
• Regorafenib + Panitumumab for Colorectal Cancers
• Intravenous BIBH 1 in Patients With Metastatic Colorectal Cancer
• Study of Fruquintinib in Patients With Metastatic Colorectal Cancer
• Cancer Associated Thrombosis and Isoquercetin (CATIQ)
• Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases
• Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer
• Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer
• Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer
• To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers
• Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
• Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis
• Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab
• [18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib
• Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US (PULSAR).
• Intestinal Microflora in Colorectal Cancer (CRC) After Chemotherapy
• S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer
• Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases
• Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)
• A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer
• Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer
• Vascular Changes During Colorectal Surgery
• A Trial of MB-6 for Reduction of Neutropenia Induced by Chemotherapy in Patients With Stage III Colorectal Cancer.
• Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal Cancer
• FOLFOXIRI Compared to FOLFOX in First Line Treatment of Metastatic Colorectal Cancer
• Acetylsalicylic Acid and Colorectal Cancer Prevention: Exploring the Platelet Function of Its Mechanism of Action
• A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
• Randomized Trial of Primary Surgery Followed Selective Radiochemotherapy for Rectal Cancer With MRI Negative CRM
• Study of Ruxolitinib in Colorectal Cancer Patients
• Efficacy And Safety Of Xeliri + Avastin Followed By Xelox + Avastin Or Reverse Sequence In Metastatic Colorectal Cancer
• Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancer
• Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer
• Molecular Fluorescence Endoscopy in Patients With Familial Adenomatous Polyposis, Using Bevacizumab-IRDye800CW
• Stivarga Regulatory Post-Marketing Surveillance Study in Korea
• Phase 2 Study With Abraxane (Nab®Paclitaxel) in Metastatic Colorectal Cancer
• A Study of Systemic Chemotherapy With/Without HAI in Patients With Initially Unresectable Colorectal Liver Metastasis
• Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma
• A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer
• Study Evaluating the Influence of LV5FU2 Bevacizumab Plus Anakinra Association on Metastatic Colorectal Cancer
• Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance "Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene" (All-patient Surveillance)
• Perioperative FOLFIRI VS Adjuvant FOLFIRI in Resectable Advanced CRC Failed to Oxaliplatin
• PERIOPERATIVE TREATMENT WITH COI-B (CAPECITABINE, OXALIPLATIN, IRINOTECAN AND BEVACIZUMAB) OF HIGH RISK OR BORDERLINE RESECTABLE COLORECTAL CANCER LIVER METASTASES
• Capecitabine Plus Aflibercept as Maintenance Therapy Following Capecitabine Plus Oxaliplatin Plus Aflibercept in Patients With Metastatic Colorectal Cancer
• Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer
• Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors
• A Phase II Study of Ziv-aflibercept in Combination With Capecitabine/Oxaliplatin (XELOX) Chemotherapy in the Front-Line Treatment of Patients With Metastatic Colorectal Cancer
• Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment
• Chemopreventive Action of Mesalazine on Colorectal Cancer: a Pilot Study for an "in Vivo" Evaluation of the Molecular Effects on β-catenin Signaling Pathway.
• Angiogenic Switch in Patients With Colorectal Cancer
• Efficacy and Tolerance of Maintenance Therapy in Patients With Incurable Advanced Colorectal Cancer
• Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients
• Recombinant Anti-tumor and Anti-virus Protein for Injection Plus Xeloda in Treatment of Metastatic Colorectal Cancer
• Study of Folic Acid, Calcium and Vitamin D in Preventing Colorectal Polyps and Colorectal Cancer
• FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer
• Escalating Doses of Oxaliplatin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Children and Adolescents With Extensive Colon Carcinoma
• Xeloda Maintenance Versus BSC in Metastatic Colorectal Cancer
• An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread
• Intravenous Iron: Measuring Response in Anemic Surgical Patients
• Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome
• Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer
• Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer
• Maintenance Chemotherapy for Metastatic Colorectal Carcinoma and Biological Marker
• MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer
• Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC
• A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer
• Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia
• Near-Infrared Imaging of Peritoneal Carcinomatosis From Colorectal Cancer
• Maintenance Treatment With Capecitabine in Colorectal Cancer Patients
• A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer Patients
• Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in mCRC
• Phase I Study to Evaluate Safety, Tolerability, Anti-Tumour Activity and PK Profiles of Foxy-5 in Metastatic Breast, Colon or Prostate Cancer
• Resection vs no Resection of the Primary in Colorectal Cancer With Unresectable Metastases
• Irinotecan -Eluting LC Bead-M1 (DEBIRI-M1) for Patients With Liver Metastases From Colorectal Cancer
• A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body
• Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.
• A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
• Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer
• Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal Cancer
• A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC
• Study of Andrographolides With or Without Capecitabine to Treat Colorectal Cancer
• Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer
• The Relationship Between Relaxation or Wheat Germ Juice to the Immune Indices and Quality of Life (QoL) in Colorectal Cancer Patients on Adjuvant Chemotherapy
• Genistein in Treatment of Metastatic Colorectal Cancer
• Diagnostic Accuracy of Ferumoxytol-Enhanced MRI for Detecting Lymph Node Metastases in Colorectal Cancer
• Monocentric Prospective Pilot Study Evaluating the Value of Indocyanine Green (ICG, Indocyanine Green) During a Surgical Resection of Cancerous Lesions Peritoneal Colorectal Origin.
• A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
• Study of TLBZT Based Herbal Therapy Plus Chemotherapy for Metastatic Colorectal Cancer
• A Phase Ib Study of Fruquintinib in 3rd Line mCRC
• Intraoperative Intraportal Chemotherapy Combined With Adjuvant Chemotherapy for Stage II and III Colorectal Cancer
• Avastin in Combination With Chemotherapy for RAS Mutant Unresectable Colorectal Liver-limited Metastases
• SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)
• Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer
• Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer
• Investigating the Use of Regorafenib (Stivarga®) in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy
• Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases
• Study of Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Cancer in Asia
• Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient
• Linaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers
• Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers
• Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis With Polyposis Nasi
• RAS Switch in Patients With Metastatic RAS Native Colorectal Tumors Treated With 1st Line FOLFIRI-Cetuximab
• Metformin and 5-fluorouracil for Refractory Colorectal Cancer.
• Short-Infusion Ziv-aflibercept in Treating Patients With Metastatic Colorectal Cancer Receiving Combination Chemotherapy
• Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo-Controlled Phase-III STudy
• Magnesium and Rotational Thromboelastometry (ROTEM) in Colorectal Cancer Surgery
• A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer
• Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT
• Metformin Plus Irinotecan for Refractory Colorectal Cancer
• Regorafenib Assessment in Refractory Advanced Colorectal Cancer(RegARd-C)
• A Phase II Trial of Salvage Treatment With Gemcitabine and S-1 Combination in Patients With Heavily Treated Advanced Colorectal Cancer.
• Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors
• A Phase II Study to Determine the Safety and Efficacy of Second-line Treatment With Metformin and Chemotherapy (FOLFOX6 or FOFIRI) in the Second Line Threatment of Advanced Colorectal Cancer
• A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer
• Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer
• Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer
• S-1 Versus Capecitabine in the First Line Treatment of MCC Patients.
• A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer
• Safety Study of Bevacizumab Plus Chemotherapy To Treat Metastatic Colorectal Cancer
• Gemcitabine in Combination With Pemetrexed Long Term Infusion in the Treatment of Pretreated Metastatic Colorectal Cancer Patients
• Phase II Study of Minocycline for Reducing Symptom Burden in Colorectal Patients
• Preoperative Valproic Acid and Radiation Therapy for Rectal Cancer
• Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer
• Comparing HAI-90Y (SIR-spheres)+Chemotx LV5FU2 Versus Chemotx LV5FU2 Alone to Treat Colorectal Cancer
• Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects
• Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer
• Maintenance Dovitinib for Colorectal and Pancreas Cancer
• A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan
• Phase II Study of Maintenance Capecitabine to Treat Resectable Colorectal Cancer
• Sequential Treatment Strategy for Metastatic Colorectal Cancer
• Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)
• Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer
• Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients
• A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors
• LOTCOL Study: Local Treatment of Colo-rectal Liver Met
• Nordic 8 - A Phase II Trial
• Phase I/II Trial of Antagonism of HER in GI Cancer
• An Observational Study of Bevacizumab in Chinese Patients With Metastatic Colorectal Cancer
• Effect of Curcumin on Dose Limiting Toxicity and Pharmacokinetics of Irinotecan in Patients With Solid Tumors
• Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors
• Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI.
• Surgery Plus Sulindac or Surgery Alone for Advanced Colorectal Cancer
• First-line Irinotecan, Lederfolin and 5FU (FOLFIRI) and Bevacizumab in Patients With Advanced Colorectal Cancer
• Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy
• Evaluation of Low-dose Irinotecan and Cyberknife® SBRT to Treat Colorectal Cancer With Limited Liver Metastasis
• A Bioequivalence Study of Capecitabine Tablets
• Phase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast Cancers
• Regorafenib Post-marketing Surveillance
• NK Activity Modulation Induced by Intravenous Lidocaine During Colorectal Laparoscopic Surgery
• Intra-arterial Hepatic Beads Loaded With Irinotecan With Concomitant Chemotherapy With FOLFOX in Patients With Colorectal Cancer With Unresectable Liver Metastases: a Phase II Multicenter Study
• Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases
• Pharmacodynamic Evaluation of Stool Output Following Oral Administration of Various Low Volume PEG3350-based Gut Cleansing Solutions Using the Split Dose Intake in Healthy Subjects
• Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases
• Endostar Combined With mFOLFOX6 for First-line Treatment of Metastatic Colorectal Cancer
• Cetuximab Rechallenge Study
• BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma
• An Open-Labeled Pilot Study of Biomarker Response Following Short-Term Exposure to Metformin
• ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis
• Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab
• Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
• Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases
• A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer
• A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer
• Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases
• Vemurafenib and Panitumumab Combination Therapy in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer
• Oral Iohexol for Fecal/Fluid Tagging for CT Colonography: A Study to Improve Image Quality by Preventing Colonic Bubbles
• Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery
• Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines
• A Randomized Prospective Trial Comparing Polyethylene Glycol and Sodium Picosulphate With Magnesium Citrate
• A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
• A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
• Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer
• Bevacizumab Therapy Untreated Unresectable Liver Metastases From Colorectal Cancer
• A Study of Famitinib in Patients With Advanced Colorectal Cancer
• Dose Escalation Study MORAb-066 Targeting TF-expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC
• Chemoradiotherapy for Patients With Oligometastatic Colorectal Cancer
• BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
• Does Administration of Antibiotics in Patients Undergoing Surgery for Colorectal Cancer Result in Less Complications and Better Prognosis?
• wXELIRI Versus FOLFIRI Regimen in the Treatment of Advanced Colorectal Cancer Patients
• CCR5-blockade in Metastatic Colorectal Cancer
• Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas
• A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer
• Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer
• FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
• Phase I Platinum Based Chemotherapy Plus Indomethacin
• Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
• Optimization of Bevacizumab Scheduling With Chemotherapy for Metastatic Colorectal Cancer
• Cetuximab for Elderly Patients With mCRC
• Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors
• Feasibility of an Immediate Preoperative Chemotherapy Before Resection fo Colorectal Cancer
• An Observational Study of First-Line Bevacizumab (Avastin) With Fluoropyrimidine-Based Chemotherapy in Participants With Metastatic Colorectal Cancer
• Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors.
• Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques
• Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic
• Biomarker Directed Treatment in Metastatic Colorectal Cancer
• IVICA: Intravenous Iron in Colorectal Cancer Associated Anaemia
• An Observational Study of First-Line Capecitabine Based Chemotherapy in Participants With Metastatic Colorectal Cancer
• Xenon Combined With Intraoperative Thoracic Epidural Analgesia
• Efficacy and Patient Satisfaction of Miralax and Gatorade Versus Movi Prep
• A Study of Bevacizumab Plus 5-Flurouracil (5-FU) Based Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Previously Untreated Unresectable Liver-Only Metastases From Colorectal Cancer
• The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
• A Multi-centre Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate)
• Study of Bevacizumab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer
• Intra-arterial Hepatic Bevacizumab and Systemic Chemotherapy
• Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer
• ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer
• Colorectal Cancer Metastatic
• Adjuvant Aflibercept for Metastatic Colorectal Cancer
• Maintenance Metronomic Chemotherapy for Metastatic Colorectal Carcinoma
• Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of QoL in Patient With Ras-wt Colorectal Cancer
• An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer, Colon Cancer in the Adjuvant Setting, Advanced Gastric Cancer or Breast Cancer
• Lymphatic Mapping for Sentinel Node Identification and Analysis
• Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer
• Fish Oil Supplementation, Nutrigenomics and Colorectal Cancer Prevention
• A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy
• Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC)
• Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer
• Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases
• Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC)
• Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and
• Study to Evaluate the Efficacy and Safety of FOLFIRI-AD in Patients With Metastatic Colorectal Cancer UGT1A Genotype 1
• Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
• Perioperative vs Postoperative Chemotherapy + Bevacizumab in Colorectal Cancer, Liver Mets
• Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth
• Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
• Chemoembolisation With CPT11 Loaded DC Bead With Cetuximab and 5FU/LV in First Line in Patients With KRAS Wildtype mCRC
• Second Look Laparoscopy in Colorectal Cancer
• Desmopressin (DDAVP) in Patients With Colorectal Cancer and Rectal Bleeding
• Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Labe
• Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer
• A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer
• Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
• Comparative Efficacy of Water & Indigo Carmine vs. Water or Air Method on Adenoma Detection Rate (ADR) - a Randomized Controlled Trial (RCT)
• The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal Cancer
• Dose Finding Study of Once or Twice Weekly IMMU-130 in Metastatic Colorectal Cancer
• P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer.
• ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER.
• A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer
• Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
• Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
• Efficacy of Vitamin D in Colorectal Cancer Chemoprevention
• Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
• BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer
• FOLFIRI or mFOLFOX6 in Adjuvant Chemotherapy in Advanced Colorectal Cancer
• Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer
• Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA
• Study of CMAB009 to Treat KRAS Wild Type Metastatic Colorectal Cancer
• Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer
• Combined Anticancer Treatment of Advanced Colon Cancer
• Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
• Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking
• Circulating Regulatory Lymphocytes and Outcome of Metastatic Colorectal Cancer Patients
• 2nd-line Treatment of Metastatic Colorectal Cancer
• Dose Finding and Pharmacokinetics/Pharmacodynamics Study of Apatinib in the Treatment of Advanced Colorectal Cancer
• Study of Bevacizumab in Combination With Alternating Xeliri and Xelox in Metastatic Colorectal Cancer
• Efficacy and Safety Study of Recombinant Endostatin Combined With Chemotherapy to Treat Advanced Colorectal Cancer
• A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis
• Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients
• Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
• Colorectal Cancer (CRC) Cetuximab Elderly Frail
• Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
• Trial Comparing Moviprep and Phosphoral as Bowel Prep Before Colonoscopy
• Study of Vitamin D in Untreated Metastatic Colorectal Cancer
• PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery
• Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases
• Profile of Soluble and Cellular Biomarkers and of Functional Imaging During Antiangiogenic Therapies in Cancer Patients
• Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
• Randomized Phase II Adjuvant Chemotherapy ± FANG™ in Colorectal Carcinoma With Liver Metastases
• Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer
• BKM120 in Cancers With PIK3CA Activating Mutations
• A Study of Capecitabine Rapid Disintegrating Tablets (RDT) Versus Commercial Xeloda in Patients With Solid Tumours
• Combining Curcumin With FOLFOX Chemotherapy in Patients With Inoperable Colorectal Cancer
• A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)
• Assessment of Tumor Vascular Effects of Axitinib With Dynamic Ultrasonography in Patients With Metastatic Colorectal Cancer
• Axitinib as Maintenance Treatment in Patients With Metastatic CRC
• Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)
• Feasibility Study on Stem Cells Sensitivity Assay
• Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
• A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
• A Phase II Study of Gemcitabine and Capecitabine for Treatment Resistant, Metastatic Colorectal Cancer
• Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer
• Intra-operative Chemotherapy With 5-FU for Colorectal Cancer Patients Receiving Curative Resection: Efficacy and Safety
• Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)
• Extended Peri-operative Tinzaparin to Improve Disease-free Survival in Patients With Resectable Colorectal Cancer
• A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
• Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype
• Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases
• Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab
• An Observational Study of Adjuvant Treatment With Capecitabine (Xeloda) in Combination With Oxaliplatin in Participants With Stage III Colon Cancer
• Impact of Pretreatment With Metformin on Colorectal Cancer Stem Cells (CCSC) and Related Pharmacodynamic Markers
• First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal Cancer
• TKM 080301 for Primary or Secondary Liver Cancer
• A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
• Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients
• Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)
• SKIP - A Double-blind Placebo-controlled Randomized Multicenter Trial of Skin Toxicity Treatment
• FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
• 1st Line Chemotherapy Alone or With Bevacizumab in Treating Older Patients With Metastatic Colorectal Cancer
• Randomized Trial With Dendritic Cells in Patients With Metastatic Colorectal Cancer
• Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer
• Gemcitabine-UFTE Chemotherapy in Refractory Colorectal Cancer
• A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer
• An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer
• Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma
• Clinical and Biological Effects of Anti-IgE (Omalizumab) in Patients With Bilateral Nasal Polyposis and Asthma
• Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
• Irinotecan, Cetuximab and Everolimus to Patients With Metastatic Colorectal Cancer
• Recombinant Anti-tumor and Anti-virus Protein for Injection in Treatment of Metastatic Colorectal Cancer
• Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients
• A Study of Bevacizumab and Modified FOLFOX-6 (mFOLFOX-6) in Participants With Metastatic Colorectal Cancer
• Does Acne Rash During Adolescence Predict Skin Reaction to Cetuximab
• Safety Study of Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma
• Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy
• Liposome-encapsulated Irinotecan Hydrochloride PEP02 or Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil as Second-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
• Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC)
• Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF
• Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer
• Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors
• TRICC-C (AIO-KRK-0111): BIBF 1120 Versus Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC)
• FOLFOXIRI Plus Panitumumab In Kras and Braf Wild-Type Metastatic Colorectal Cancer
• A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
• S0820, Adenoma and Second Primary Prevention Trial
• Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Standard Chemotherapy in Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy Failure
• Study With Dendritic Cell Immunotherapy in Resected Hepatic Metastasis of Colorectal Carcinoma
• Effect of Intravenous Lidocaine on the Tolerability of Early Oral Feeding After Laparoscopic Colorectal Surgery
• Ginger for Colorectal Cancer Prevention
• Study of Aprepitant / Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Colorectal Cancer Patients - SENRI Trial
• Exercise and Metformin in Colorectal and Breast Cancer Survivors
• A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-Naïve Patients With Metastatic Colorectal Cancer With or Without K-RAS Mutations, and Comparison to Cetuximab
• Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads
• Curcumin Biomarkers
• MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma
• Neoadjuvant Study of Recombinant Vaccinia Virus to Treat Metastatic Colorectal Carcinoma in Patients Undergoing Complete Resection of Liver Tumors
• FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)
• Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
• A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
• Comparative Study of Lubiprostone and PEG Preparation Versus Conventional PEG Preparation for Colonoscopy
• Study of Cetuximab in Combination With mFOLFOX-6 (Oxaliplatin, Leucovorin, 5-FU) to Treat Colorectal Liver Metastatic Cancer Patients
• Study of Irinotecan Plus Capecitabine to Treat Advanced Colorectal Cancer
• Efficacy of FOLFOX+Bevacizumab in Combination With Irinotecan in the Treatment of Metastatic Colorectal Cancer
• Epidural Versus Patient-controlled Analgesia for Reduction in Long-term Mortality Following Colorectal Cancer Surgery
• Pre-emptive Cycline Treatment on Cetuximab Induced Skin Toxicity in Colorectal Cancer
• FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema
• Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer
• Trial of Metformin for Colorectal Cancer Risk Reduction for History of Colorectal Adenomas and Elevated BMI
• A Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer
• A Trial of Pre-Operative Chemoradiotherapy Using Capecitabine, Radiation & Cetuximab, in Rectal Cancer
• Recombinant Human Endostatin in Combination With mFOLFOX6 in Patients With Metastatic Colorectal Cancer
• Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
• New Adjuvant Chemotherapy of Non Resectable Liver Metastasis of Colorectal Cancer Without Bleeding, Obstruction
• A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
• Evaluating the Safety and Efficacy of SB Injection in Patients With Advanced or Metastatic Colorectal Cancer
• A Trial of Irinotecan and BKM120 in Previously Treated Advanced Colorectal Cancer
• A Study of the Safety and Biological Activity of Intraperitoneal (IP) EGEN-001 Administered Alone and in Combination With Standard Chemotherapy in Colorectal Peritoneal Carcinomatosis Patients
• Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer
• Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
• IXO+A in mCRC With Liver-only Metastases
• Sorafenib Plus Capecitabine Efficacy Assessment in Patients With Advanced Pre-treated Colorectal Cancer
• Trial of FOLF(HA)Iri Versus FOLFIRI in mCRC
• First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib
• Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal Cancer
• A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B)
• Effect of Celecoxib on Perioperative Inflammatory Response in Colon Cancer
• Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC)
• Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
• Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer
• 4SC-201 (Resminostat) in Advanced Colorectal Carcinoma
• Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab
• Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer
• Study of TF2 Carcinoembryonic Antigen (CEA) Antibody in Patients With Metastatic Colorectal Cancer
• Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients
• Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer
• Study of IMMU-130 in Patients With Relapsed/Refractory Colorectal Cancer
• Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer
• Oxaliplatin, Leucovorin, and Fluorouracil Before and After Radiation Therapy and Surgery in Treating Patients With Rectal Cancer That Can Be Removed by Surgery
• A Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases
• L19TNFα in Patients With Advanced Solid Tumors
• Phase 1 and 2 Study of PX-866 and Cetuximab
• Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
• Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC
• Dual Targeting of Vascular Endothelial Growth Factor-A Together With Angiopoietins in Chemotherapy-naïve Metastatic Colorectal Cancer
• A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)
• Intermittent Versus Continuous Tarceva Study
• Oral Green Tea Extract and Milk Thistle Extract to Colorectal Cancer Patients Undergoing Resection
• Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy
• Study of NK012 and 5-FU/LV in Solid Tumors Followed by Dose Expansion in Colorectal Cancer
• Trial of XELIRI/FOLFIRI + Simvastatin Followed by Simvastatin Maintenance in Metastatic Colorectal Cancer
• Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.
• A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (
• A Study of Avastin (Bevacizumab) Plus Xeloda (Capecitabine) in Patients With Locally Advanced Rectal Cancer.
• FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
• Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy
• A Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer
• RSHF in Colorectal Cancer
• FOLFOXIRI Compared With FOLFIRI for Metastatic Colorectal Cancer
• Study of Panitumumab-Capecitabine-Oxaliplatin In Wild-Type K-Ras Metastatic Colorectal Cancer Patients
• Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer
• Response Prediction in Metastasized Colorectal Cancer Using Intratumoral Thymidylate Synthase
• Colon Cancer Prevention Using Selenium
• Efficacy Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma
• FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer
• Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium With or Without Zibotentan in Treating Patients With Metastatic Colorectal Cancer
• High-Dose Cholecalciferol in Treating Patients Receiving Combination Chemotherapy and Bevacizumab as First-Line Therapy For Metastatic Colorectal Cancer
• Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer
• Nasal Packing as a Drug Delivery System Postoperatively in Chronic Sinusitis With Polyposis
• Combination Chemotherapy Treatments in Patients With Colorectal Cancer Stage II and III
• Azacitidine and CAPOX in Metastatic Colorectal Cancer
• S-1/Leucovorin (SL) Versus sLV5FU2 as the First-line Treatment for Elderly Patients With Colorectal Cancer
• Cetuximab and Simvastatin in Treating Patients With Advanced or Metastatic Colorectal Cancer
• A Study of FOLFIRI Plus OMP-21M18 as 1st or 2nd-line Treatment in Subjects With Metastatic Colorectal Cancer
• Clinical Evaluation - A Phase IIA Proof of Concept Study of Regorafenib (Bayer 73-4506) in Biopsy-amenable Asian Colorectal Cancer Patients
• A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients
• Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer
• Predictive Value of 99mTc- Albumin Spheres Before 90Y- SIR Therapy
• Lapatinib and Cetuximab in Patients With Solid Tumors
• A Study in Second Line Metastatic Colorectal Cancer
• A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients
• A Study of Avastin (Bevacizumab) Combined With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
• FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer
• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
• A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum.
• Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer
• Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy
• First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal Cancer
• PET-CT and Circulating Tumor Cells in Colorectal Cancer
• Safety and Efficacy Study of mFOLFOX-6 Plus Cetuximab for 8 Cycles Followed by mFOLFOX-6 Plus Cetuximab or Single Agent Cetuximab as Maintenance Therapy in Patients With Metastatic Colorectal Cancer and WT KRAS Tumours
• A Study of Avastin (Bevacizumab) and Oxaliplatin Plus Xeloda (Capecitabine) in Patients With Advanced Colorectal Cancer.
• Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer
• A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer
• High Dose Vitamin D Study
• Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
• Preventive Effect of Enoxaparin, Pentoxifylline and Ursodeoxycholic Acid to Radiation Induced Liver Toxicity
• A Dose-finding Study of RO5323441 in Patients With Metastatic Treatment-Refractory Colorectal or Ovarian Cancer
• A Clinical Trial of Panitumumab in Combination With FOLFIRI Chemotherapy as Second Line Treatment in Subjects With Metastatic Colorectal Cancer Expressing Wild-type KRAS and Who Had Progressed ≥ 6 Months After the Last Dose of the First Line Chemo
• A Study of RO5212054 (PLX3603) in Participants With BRAF V600-Mutated Advanced Solid Tumors
• Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer
• A Study of Avastin (Bevacizumab) in Combination With Xelox and Tarceva in Patients With Metastatic Colorectal Cancer.
• An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer
• FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer
• A Study of Avastin (Bevacizumab) in Combination Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
• Curative Resectability of Not Optimally Resectable Liver and/or Lung Metastases From Colorectal Carcinoma (CRC) Under Intensified Chemotherapy
• Study of CS-1008 in Combination With FOLFIRI in Patients Who Have Failed Other Treatments
• Sym004 in Patients With Advanced Solid Tumors
• RO4929097 in Treating Patients With Metastatic Colorectal Cancer
• Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec
• A Study of Ramucirumab or Icrucumab in Colorectal Cancer
• Feasibility Study of SOL (S-1,Oral Leucovorin,and Oxaliplatin) for Colorectal Cancer in China
• Simvastatin and Panitumumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
• Pemetrexed and Gemcitabine for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations
• Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer
• Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
• Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy
• Study of Micrometastases in Patients With Stage I or Stage II Localized Colon Cancer That Can Be Removed by Surgery
• Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
• Observational Study of Bevacizumab [Avastin] in Patients With Metastatic Colorectal Cancer (AVASTART)
• Oral Glutamine in the Prevention of Oxaliplatin-induced Neurotoxicity
• Chemotherapy With or Without Surgery in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
• Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer
• MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC)
• A Korean Post-marketing Surveillance Study on Erbitux® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing Treatment
• Study Comparing Conventional and Fast Track Multi-Discipline Treatment Interventions for Colorectal Cancer
• Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy
• A Study of Avastin (Bevacizumab) With XELOX or FOLFOX in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line FOLFIRI and Avastin
• ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
• An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment
• Vitamin D Levels in Stage IV Colorectal Cancer Patients
• Selecting Treatment in Colorectal Cancer:Capecitabine or 5-fluorouracil Selection to be Combined With Oxaliplatin or Irinotecan as First-line Chemotherapy in Advanced Colorectal Cancer
• Eicosapentaenoic Acid (EPA) for Treatment of Colorectal Cancer Liver Metastases
• Prognostic Factors for Patients With Advanced Colorectal Cancer Treated With Cetuximab.
• Efficacy/Safety Study of Bevacizumab,Capecitabine,Oxaliplatin to Metastatic Colorectal Adenocarcinoma Elderly Patients.
• Safety Study of DNA Vaccine Delivered by Intradermal Electroporation to Treat Colorectal Cancer
• Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer
• TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer
• A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
• RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
• A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer
• Bi-weekly Cetuximab Combined With 5-fluorouracil/Leucovorin/Oxaliplatin (FOLFOX-6) in Metastatic Colorectal Cancer
• Effect of Enteral Nutrition Rich in Eicosapentaenoic Acid (EPA) on Patients Receiving Chemotherapy for GI Tumor
• A Phase II Trial of MB-6 Plus FOLFOX4 for Metastatic Colorectal Cancer (FDA IND 103675)
• RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma
• QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
• An Observational Study of CPT-11 Based Regimens and UGT1A1 Genotypes in Metastatic Colorectal Cancer (mCRC)
• Compare FOFLOX4 in Preoperative and Postoperative and Postoperative in Resectable Liver Metastasis Colorectal Cancer (MCC)
• A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer
• Trial Comparing Two Two Sequences of Therapy in Colorectal Metastatic Patients
• Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer
• OPTIMOX1 in Chinese mCRC Patients
• Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Untreated Unresectable Liver-only Metastases From Colorectal Cancer
• OSI-906 and Irinotecan in Patients With Advanced Cancer
• Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery
• EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer
• Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
• Cetuximab Plus Irinotecan in Colorectal Cancer Patients Who Progressed After Failure With Cetuximab Plus Irinotecan
• ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
• Evaluate Efficacy and Safety of XELOX in Potentially Resectable Liver Metastasis From Colorectal Cancer(CRC)
• Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation
• Colorectal Cancer RECHALLENGE
• Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
• Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer
• Figitumumab Combined With Pegvisomant For Advanced Solid Tumors
• Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer
• S-1 and Bevacizumab in Treating Patients With Colorectal Cancer That is Recurrent or Cannot Be Removed by Surgery
• Optimal Maintenance Therapy With Bevacizumab After Induction in Metastatic Colorectal Cancer (CRC)
• Study of Nimotuzumab to Treat Colorectal Cancer
• CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin
• Capecitabine, Panitumumab, and Radiation Therapy With or Without Irinotecan Hydrochloride in Treating Patients Undergoing Surgery for Localized Rectal Cancer
• Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
• 177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
• Sunitinib and Capecitabine for First Line Colon Cancer
• Studying Biomarkers in Tumor Tissue and Blood Samples From Patients Undergoing Chemotherapy and Radiation Therapy for Stage II or Stage III Rectal Cancer That Can Be Removed By Surgery
• Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer
• A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
• A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer
• Combination Chemotherapy for 3 Months or 6 Months in Treating Patients With Stage III Colon Cancer
• Safety and Efficacy Study of Panitumumab+Irinotecan in Patients Wild-Type (WT) KRAS Metastatic Colorectal Cancer Refractory to Irinotecan Based Chemotherapy (SPECTRA)
• Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer
• Combination Chemotherapy and Bevacizumab With or Without Bevacizumab Maintenance Therapy in Treating Patients With Metastatic Colorectal Cancer
• Methotrexate in Metastatic Colorectal Cancer With MSH2 Deficiency
• Study to Evaluate the Effects of Panitumumab if Combined With Chemotherapy for 2nd Treatment of Colorectal Cancer
• Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment
• Phase I and Pharmacokinetic Study of Biweekly PEP02 in mCRC Refractory to 1st-line Oxaliplatin Base Therapy
• Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
• OPAL Study: A Study of Avastin (Bevacizumab) in Combination With FOLFOXIRI in Patients With Previously Untreated Metastatic Colorectal Cancer
• Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery
• Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI
• CY-503 for the Treatment of Chemotherapy-refractory Metastatic Colorectal Cancer
• A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
• Use of Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP)
• Phase I Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Participants With Colorectal Cancer (MK-0646-016)
• An Open Label Phase I Study to Eval the Safety and Tolerability of a Vaccine (GI-6207) Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-expressing
• A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-
• Study of Intravenous Aflibercept in Combination With FOLFIRI in Japanese Patients With Metastatic Colorectal Cancer
• XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib
• A Clinical Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SRT501 in Subjects With Colorectal Cancer and Hepatic Metastases
• Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
• PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
• Study About Preventive Treatment of Folliculitis Induced by Epidermal Growth Factor Receptor Inhibitors
• Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors
• Xeloda or UFT (Tegafur-uracil) With Folinic Acid in Advanced or Metastatic Colorectal Cancer
• BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer
• Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
• Identifying Prognostic Factors in Patients Receiving Tegafur-Uracil for Stage II Colon Cancer That Was Completely Removed By Surgery
• Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab
• Study of S-1 Plus LV for Untreated Metastatic Colorectal Cancer
• Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone
• Thalidomide and Tegafur/Uracil(UFUR) in the Treatment of Advanced Colorectal Cancer
• Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer
• β-adrenergic Blocker and a COX2 Inhibitor for Prevention of Colorectal Cancer Recurrence
• Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases
• Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin
• KRAS Wild-type Metastatic Colorectal Cancer Trial
• Irinotecan, Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients
• Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer
• A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
• Outpatient Health Care Program for Older Patients Receiving Chemotherapy for Newly Diagnosed Breast Cancer or Colon Cancer
• Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer
• External-Beam Radiation Therapy, Capecitabine, and Sorafenib in Treating Patients With Locally Advanced Rectal Cancer
• Oxaliplatine Based Adjuvant Chemotherapy for Stage II/III Colorectal Cancer: 8 Cycles Versus 12 Cycles
• New Individualized Therapy Trial for Metastatic Colorectal Cancer
• Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases
• Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects
• A Study of Bevacizumab (Avastin) in Participants With Newly Diagnosed Locally Advanced Rectal Cancer
• A Study of IMC-1121B (Ramucirumab) in Colorectal Cancer
• Post-First Progression Use of Bevacizumab in Metastatic Colorectal Cancer (mCRC)
• Study of Pretargeted Radioimmunotherapy of a Anti-CEA Bispecific Antibody and Lu177-labeled Peptide in Colorectal Cancer
• NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
• Biomarker - Panitumumab Response With KRAS Wild Type MCC
• Oxaliplatin, Capecitabine and Endostar as First Line Treatment for Patients With Advanced Colorectal Cancer
• Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy
• A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)
• Study of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer
• Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer
• Exploratory Study Of The ERCC-1 Gene
• Coxib-inhibition of Duodenal Polyp Growth in FAP
• Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2
• Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer
• A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors
• Sorafenib and FOLFIRI Regimen in 2nd Colorectal Cancer (CRC) After Failure of Oxaliplatin Treatment
• Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
• Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery
• Study of IMC-11F8 in Participants With Colorectal Cancer
• Neo-adjuvant Chemoradiation With Oxaliplatin/5-FU in Rectal Cancer
• Macrogol 3350-based Oral Osmotic Laxative in Preventing Cancer in Patients at Risk of Colorectal Cancer
• Neoadjuvant Bevacizumab, Capecitabine and Radiation Therapy With or Without Oxaliplatin Locally Advanced Rectal Cancer
• Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations
• Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
• Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer
• Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib
• PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
• A Phase I/II Study of IXO With Bevacizumab in Patients With Metastatic Colorectal Cancer
• Chemoembolization, Irinotecan Bead, Second Line Chemotherapy Treatment of Unresectable Metastatic Colorectal Cancer
• Capecitabine and Radiation Therapy With or Without Panitumumab in Treating Patients With Advanced Rectal Cancer
• FOLFOX4 Combined With Endostar in Patients With Advanced Colorectal Cancer
• Pharmacokinetic Study of Capecitabine in Elderly Cancer Patient (≥ 75 Years)
• A Safety Study of Pentamidine in Patients With Metastatic Colon Cancer Undergoing Standard Chemotherapy as Second-line and/or Third-line Treatment
• Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis
• FOLFIRI and Sunitinib in Metastatic Colorectal Cancer
• A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
• A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer
• Bevacizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
• A Study of Xeloda (Capecitabine) Plus Radiotherapy in Participants With Locally Advanced Rectal Cancer
• Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS Mutations
• Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)
• Study of Gamma Interfereon in Metastatic Colorectal Carcinoma
• IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy (IMA910-101)
• Dual Inhibition of EGFR Signalling Using the Combination of Cetuximab and Erlotinib
• First-line Therapy of Stage IV Colorectal Cancer
• Nitrous Oxide and Risk of Cancer Recurrence After Colorectal Surgery: A Randomized, Blinded Study
• Phase I Trial of Sorafenib + FOLFIRI In Metastatic Colorectal Cancer
• A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer
• Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study)
• A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer.
• Capiri-sutent Phase-1 in Advanced Colo-rectal Cancer
• Lyophilized Black Raspberries in Adults With Familial Adenomatous Polyposis (FAP)
• Systemic Chemotherapy With or Without Intraperitoneal Chemohyperthermia in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer
• Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver
• Chemotherapy and Radiation Therapy Before Surgery Followed by Capecitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced Rectal Cancer
• Chemotherapy and Cetuximab in Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer
• Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC
• Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc
• A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma
• Combination Chemotherapy After Surgery in Treating Patients With High-Risk Stage II or Stage III Colorectal Cancer
• Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan
• Neoadjuvant FOLFOX6 + Cetuximab in Patients With Colorectal Cancer and Unresectable Liver Metastasis
• Older Patients With Newly Diagnosed Breast Cancer or Colon Cancer
• FOLFOX6 Plus Sir-Spheres Microspheres Plus Avastin in Patients With Nonresectable Liver Metastases From Colorectal Carcinoma
• A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer
• FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
• Randomized Phase II Study of SOL for Untreated Metastatic Colorectal Cancer
• Second-Line Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Who Have Received First-Line Chemotherapy and Bevacizumab
• Combination Chemotherapy and Bevacizumab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
• Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer
• Irinotecan, Capecitabine and Avastin for Metastatic Colorectal Cancer as Salvage Treatment
• Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer
• S0000D: Effect of Vitamin E and/or Selenium on Colorectal Polyps in Men Enrolled on SELECT Trial SWOG-S0000
• Nelfinavir, a Phase I/Phase II Rectal Cancer Study
• Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
• A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Colorectal Cancer
• A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.
• Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Intravenous Oxaliplatin Plus Irinotecan in Patients With Unresectable Hepatic Metastases From Colorectal Cancer
• Phase II Trial of LBH589 in Refractory Colorectal Cancer
• Irinotecan/Oxaliplatin/5-Fluorouracil/Leucovorin/Cetuximab As First Line Treatment In Colorectal Cancer
• S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer
• Celecoxib in Preventing Colorectal Cancer in Young Patients With a Genetic Predisposition for Familial Adenomatous Polyposis
• Phase II Study of Avastin + Erbitux + Irinotecan as 2nd Line Treatment of Colorectal Cancer
• Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer
• Study of S-1 and Oxaliplatin (SOX) Versus Capecitabine and Oxaliplatin (COX) in Patients With Advanced Colorectal Cancer
• Oxaliplatin and S-1 (OS) Versus Oxaliplatin and Capecitabine (XELOX) for Advanced Colorectal Cancer
• NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer
• A Study of Dulanermin Administered in Combination With Camptosar®/Erbitux® Chemotherapy or FOLFIRI (With or Without Bevacizumab) in Subjects With Previously Treated Metastatic Colorectal Cancer
• Study Of Sunitinib With FOLFIRI In Colorectal Cancer
• Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors
• Avastin/[18-F]-5-fluorouracil PET/CT Imaging Feasibility Project
• Tegafur-Uracil and Leucovorin or S-1 in Treating Patients With Stage III Colon Cancer That Has Been Completely Removed by Surgery
• FLOX + Cetuximab (Erbitux®) for Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor
• Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers
• Neo-adjuvant Therapy and the Effect on Synchronous Metastatic Growth
• Study of Colon GVAX and Cyclophosphamide in Patients With Metastatic Colorectal Cancer
• Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
• Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer
• Fluorouracil and Oxaliplatin With or Without Panitumumab In Treating Patients With High-Risk Colon Cancer That Can Be Removed by Surgery
• Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)
• A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
• A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Chinese Patients With Metastatic Colorectal Cancer.
• Curcumin in Treating Patients With Familial Adenomatous Polyposis
• Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer
• Combination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal Cancer
• Efficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Growth Factor Receptor (EGFR) Expressions
• A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer
• Study Of Sunitinib In Combination With Folfox In Patients With Colorectal Cancer
• Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study
• Phase 3 Study of Surgery Combined With Neoadjuvant Chemotherapy(XELOX) in Colorectal Cancer With Resectable Liver Metastasis
• Combination Chemotherapy and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
• Comparison of Two Methods of Administration of a PEG Solution
• Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer
• Lymphatic Mapping, Sentinel Lymph Node Analysis, and Blood Tests in Detecting and Predicting Early Micrometastases in Patients With Colorectal Cancer
• Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01)
• Capecitabine, Oxaliplatin, Selenomethionine, and Radiation Therapy in Treating Patients Undergoing Surgery For Newly Diagnosed Stage II or III Rectal Adenocarcinoma
• A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer
• Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors
• Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
• A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen
• Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)
• Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer
• Study of Enzastaurin With 5-Fluorouracil/Leucovorin (5-FU/LV) Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer
• Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer
• Celecoxib in Treating Patients With Early-Stage Rectal Cancer
• Role of Xaliproden on Recovery Rate From Severe Neuropathy in Patients Who Have Completed Adjuvant Chemotherapy With Oxaliplatin Based Regimens
• MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer
• A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer
• Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors
• NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b)
• A Pilot Study of PPX in Women With Metastatic Colorectal Cancer
• Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- Tarceva
• Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus
• Phase I/II Combination With Irinotecan- Erbitux
• Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer
• Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
• Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)
• Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib
• Trial of Aspirin and Arginine Restriction in Colorectal Cancer
• A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.
• OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum.
• Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer
• Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma
• Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer
• Phase II Trial of Combination Therapy With Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients With Unresectable or Recurrent Colorectal Cancer
• Phase II Trial of Combination Therapy With Bevacizumab and S-1 in Elderly Patients With Unresectable or Recurrent Colorectal Cancer (BASIC)
• Phase II Trial of Combination Therapy With S-1, Irinotecan, and Bevacizumab (SIRB) in Patients With Unresectable or Recurrent Colorectal Cancer
• Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers
• Effect of Panitumumab on the Pharmacokinetics of Irinotecan
• Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen
• Cetuximab and Combination Chemotherapy in Treating Patients With Advanced or Metastatic Colorectal Cancer
• Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer
• Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung
• Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
• Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer
• Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
• A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)
• Leucovorin, Fluorouracil, Cetuximab, and Oxaliplatin in Treating Patients With Stage IV Colorectal Cancer and Liver Metastases That Cannot Be Removed by Surgery
• Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
• G-CSF in Preventing Neutropenia During First-Line Treatment With Chemotherapy and Bevacizumab in Patients With Metastatic Colorectal Cancer
• Radiation Therapy, Chemotherapy, and Cetuximab Followed by Surgery, Chemotherapy, and Cetuximab in Treating Patients With Locally Advanced or Metastatic Rectal Cancer That Can Be Removed by Surgery
• Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer
• Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment
• Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement
• Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer
• AZD2281 and Irinotecan in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer
• Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer
• A Phase I/II Trial of TS-1 and Oxaliplatin in Patients With Advanced Colorectal Cancer
• Phase II Study to Evaluate Safety and Efficacy of Cetuximab in Combination With XELOX for 12 Weeks Followed by Maintenance Treatment With Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer.
• Phase I/II Study of SOL for Untreated Metastatic Colorectal Cancer
• Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer
• Phase II Efficacy Study of AZD6244 in Colorectal Cancer
• Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery
• Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA
• Trial of Antibiotic Prophylaxis in Elective Laparoscopic Colorectal Surgery: Oral and Systemic Versus Systemic Antibiotics
• Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer
• Study of Genetic Polymorphisms of Drug Transporters and Orphan Nuclear Receptors on Treatment Effects of Irinotecan
• Phase II Study of Irinotecan,Oxaliplatin Plus TS-1 in Untreated Metastatic Colorectal Cancer
• A Phase I Study of S-1 Plus Irinotecan and Oxaliplatin in Advanced Gastrointestinal Malignancy
• Study of Irinotecan & Capecitabine in Metastatic Colorectal Cancer
• Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer
• Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers
• A Study of Xeloda (Capecitabine) as Adjuvant Monotherapy in Patients With Colon Cancer.
• FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer
• A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer
• Phase I FOLFOX Combination
• Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy
• A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer
• A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g)
• Uracil and Tegafur/Leucovorin (UFT/LV) Versus UFT/LV+ Polysaccharide-K (PSK) for Stage IIIa/IIIb Colorectal Cancer
• Gemcitabine, Capecitabine, and Oxaliplatin as Second-Line Therapy in Treating Patients With Advanced Colorectal Cancer Previously Treated With Irinotecan
• Phase I Efficacy On Vascular Permeability In Patients With Advanced Colorectal Cancer
• A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX
• Study of Nimotuzumab and Irinotecan in Metastatic Colorectal Cancer
• Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver
• A Study of Bevacizumab (Avastin) in Combination With Capecitabine (Xeloda) in Elderly Patients With Metastatic Colorectal Cancer
• A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer
• Study of NGR-hTNF as Single Agent in Patients Affected by Colorectal Cancer (CRC)
• Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer
• Double-Blind Randomized Placebo-Controlled Trial on Clinical and Biological Effects of Oral Corticosteroids or Doxycyclin in Patients With Nasal Polyposis
• Safety and Efficacy of Folfox4 + Weekly Cetuximab vs Folfox 4+Biweekly Cetuximab by Metastatic Colorectal Cancer
• A Study of Picoplatin in Colorectal Cancer
• A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
• Panitumumab in Combination With Irinotecan Chemotherapy as 2nd-line Therapy in Subjects With mCRC
• Preoperative Non-steroidal Anti-inflammatory Drugs(NSAID) to Colorectal Cancer Patients
• Randomized Phase III Study of Folfiri+Avastin Versus Xeliri+Avastin as 1st Line Treatment of CRC
• Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
• Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery
• A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors
• Combination Chemotherapy and Bevacizumab With or Without Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer
• Comparison of Bowel Preparation in Virtual Colonoscopy (VC) - Patient Experience
• Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer
• Study of the Antitumor Activity of Capecitabine in Combination With Erlotinib in Patients With Metastatic Colorectal Cancer
• Intraperitoneal Hyperthermic Perfusion With Oxaliplatin in Treating Patients With Stage IV Peritoneal Cancer Due to Appendix Cancer or Colorectal Cancer
• Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer
• A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients
• Study of XL281 in Adults With Solid Tumors
• Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer
• Arsenic Trioxide, Fluorouracil, and Leucovorin in Treating Patients With Stage IV Colorectal Cancer That Has Relapsed or Not Responded to Treatment
• Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer
• Pre- and Postoperative Chemotherapy Including Bevacizumab in Potentially Curable Metastatic Colorectal Cancer
• Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer
• Maintenance Treatment Versus Observation After Induction in Advanced Colorectal Carcinoma
• Phase 3 Trial of Litx™ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases
• Study to Evaluate the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab.
• Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer
• A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer
• ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal Cancer
• 5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)
• Resveratrol in Treating Patients With Colorectal Cancer That Can Be Removed By Surgery
• Capecitabine and Oxaliplatin or Standard Follow-Up Care in Treating Patients Who Have Undergone Surgery for Locally Advanced Rectal Cancer
• Fluorouracil, Semustine, and Vincristine Compared With BCG in Treating Patients With Dukes' B or Dukes' C Colon Cancer That Has Been Removed By Surgery
• Liver Infusions of Fluorouracil in Treating Patients With Dukes' A, Dukes' B, or Dukes' C Colon Cancer Undergoing Surgery
• Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment
• Fluorouracil and Leucovorin and/or Levamisole After Surgery In Treating Patients With Dukes' B Or Dukes' C Colon Cancer
• Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
• Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED)
• Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan in First-Line Treatment of Metastatic Colorectal Cancer
• Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy
• SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial
• Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer
• Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment
• Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer
• Chemotherapy and Internal Radiation in Treating Patients With Colorectal Cancer That Has Spread to the Liver
• VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer
• Safety Study of PLX4032 in Patients With Solid Tumors
• Study to Evaluate Progression Free Survival in Cancer Patients With Advanced Colorectal Carcinoma With AMT2003
• A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer
• TREE-2: Three Regimens of Eloxatin in Advanced Colorectal Cancer
• Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer
• Tailored Treatment in Metastatic Colorectal Cancer
• Adjuvant Xeloda Plus Eloxatin +/- Avastin After Radical Resection of Liver Metastasis of Colorectal Cancer
• Tegafur-Uracil or Observation in Treating Patients With Stage II Colorectal Cancer That Has Been Completely Removed By Surgery
• Radiation Therapy, Irinotecan, and Cetuximab in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Rectal Cancer
• Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy
• Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil
• A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer
• Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin)
• Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer
• Chemoradiation for Locally Advanced and Low Rectal Cancers: Avastin-Capecitabine-Oxaliplatin-Radiation REctal Cancer Trial
• A Phase III Trial Comparing UFT+PSK to UFT+LV in Stage IIB, III Colorectal Cancer
• Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors
• ChronoFOLFOX Plus Avastin for Patients With Metastatic Colorectal Cancer
• First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
• Oxaliplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients Undergoing Surgery for High-Risk Rectal Cancer
• Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX
• Prevention And Treatment Of Chemotherapy-Induced Peripheral Neuropathy In Subjects With Advanced Colorectal Cancer
• 131-I-TM-601 Study in Adults With Solid Tumors
• Combination Chemotherapy in Treating Patients With Resected Colon Cancer
• A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.
• Phase II Study of Bevacizumab, Capecitabine and Oxaliplatin in Colon Cancer
• PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy
• A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma
• Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer
• SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer
• Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients
• A Study of Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Metastatic Colorectal Cancer.
• A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.
• Clinical Study of Capecitabine, Oxaliplatin and Bevacizumab in Colorectal Cancer
• 1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR.
• AZD2171 and Standard Combination Chemotherapy in Advanced Non-Small Cell Lung Cancer or Colorectal Cancer
• Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone
• A Phase I Study of ECO-4601 in Patients With Advanced Cancer
• Phase II Trial of RAD001 in Refractory Colorectal Cancer
• Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer.
• Celecoxib, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer That Can Be Removed By Surgery
• Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy
• Vorinostat and IV Fluorouracil/Leucovorin (5FU/LV) in Patients With Metastatic Colorectal Cancer
• Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer
• Study of Bevacizumab Alone or Combined With Capecitabine and Oxaliplatin as Support Therapy in Metastatic Colorectal Cancer Patients
• Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy
• Nitric Oxide-Releasing Acetylsalicyclic Acid in Preventing Colorectal Cancer in Patients at High Risk of Colorectal Cancer
• Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal Cancer
• Elaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and Bevacizumab) in Patients With Colorectal Cancer and Liver Metastases
• BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer
• FOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer
• Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colon Cancer That Cannot Be Removed By Surgery
• Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab
• Irinotecan Discontinuation and Reintroduction for Advanced Colorectal Cancer
• Influence of Sulindac and Probiotics on the Development of Pouch Adenomas in Patients With Familial Adenomatous Polyposis
• Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery
• IRIS Followed by mFOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer
• Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon
• Phase II Study of Simvastatin Plus Irinotecan, Fluorouracil, and Leucovorin(FOLFIRI) for Metastatic CRC
• Study of Ticilimumab in Patients With Metastatic Colorectal Cancer Whose Disease Had Progressed After Treatment
• Sequential Versus Combination Chemotherapy in Advanced Colorectal Carcinoma
• Liposomal SN-38 in Treating Patients With Metastatic Colorectal Cancer
• Thalidomide in Treating Patients Who Have Undergone Surgery and Chemotherapy for Cancer That Has Spread Throughout the Abdomen Due to Colorectal Cancer or Appendix Cancer
• A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors
• 5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer
• Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer
• Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.
• Combination Chemotherapy as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
• Irinotecan With or Without Capecitabine as Second-Line Therapy in Treating Older Patients With Progressive, Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
• Radiation Therapy With or Without Chemotherapy Before Surgery in Treating Patients With Stage II or Stage III Rectal Cancer
• Dose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer
• The MAX Study: Mitomycin C, Avastin and Xeloda in Patients With Untreated Metastatic Colorectal Cancer
• Phase I/II CT 2106 and 5-FU/FA in Colorectal Cancer
• Capecitabine and 131I-huA33 in Patients With Metastatic Colorectal Cancer
• Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery
• Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer
• Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal Cancer
• High Dose Simplified Folfiri in Advanced Colorectal Cancer: a Multicentre Phase II Study
• Early Detection of Polyps and Colon Cancer by Fluorescence Imaging - a Dose-finding Study
• Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer
• Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line Chemotherapy of Unresectable Colorectal Cancer
• Biomarkers in Patients With Rectal Cancer Undergoing Chemotherapy and Radiation Therapy
• Bortezomib, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Rectal Cancer
• Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX)
• Study of XL999 in Patients With Metastatic Colorectal Cancer
• Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer
• Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
• Aspirin/Folate Prevention of Large Bowel Polyps
• XENOX - Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy
• A Study of Mitomycin C, Irinotecan, and Cetuximab
• Oxaliplatin and Capecitabine With or Without an Hepatic Arterial Infusion With Floxuridine in Treating Patients Who Are Undergoing Surgery and/or Ablation for Liver Metastases Due to Colorectal Cancer
• Combination Chemotherapy in Treating Patients With Colorectal Cancer and Resectable Metastases
• Combination Chemotherapy and Radiation Therapy in Treating Patients With Recurrent Metastatic Colorectal Cancer
• Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
• Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM)
• Combination Chemotherapy With or Without Cetuximab in Treating Patients With Stage III Colon Cancer That Was Completely Removed By Surgery
• A Study of ADH300004 in Surgically Resected Primary or Metastatic Colorectal Cancer and Liver Biopsy, or Planned Hepatic Resection
• GM-CSF and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Colon Cancer
• Celecoxib, Capecitabine, and Irinotecan in Treating Patients With Recurrent or Metastatic Colorectal Cancer
• Study of Glutamine as Prophylaxis for Irinotecan Induced Diarrhea
• Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer.
• Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer
• A Phase II Trial of Modified FOLFOX 6 and Cetuximab in First Line Treatment of Metastatic Colorectal Cancer
• First-Line Capecitabine and Cetuximab for Metastatic Colorectal Ca in Elderly Patients
• Gene Expression Analysis of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin Based Chemotherapy Regimen
• Use of Curcumin in the Lower Gastrointestinal Tract in Familial Adenomatous Polyposis Patients
• Hepatic Artery Infusion With Oxaliplatin
• IRESSA™ In Combo With Xeloda™ in Advanced Colorectal Cancer Patients After 1st-Line Chemo Failure
• Safety and Efficacy Study of Intravenous Lidocaine After Colorectal Surgery: LIDOREHAB
• A Phase 2 Study of Tomudex & Iressa as Second Line Chemotherapy in Subjects With Colorectal Carcinoma
• Irinotecan, 5-Fluorouracil and Leucovorin With or Without Iressa in the Treatment of Metastatic Colorectal Cancer
• Combination Chemotherapy Treatments in Patients With Metastatic Colorectal Cancer
• Intra-op Lidocaine and Ketamine Effect on Postoperative Bowel Function
• Radiation Therapy and Capecitabine With or Without Oxaliplatin in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Rectal Cancer
• Capecitabine and Oxaliplatin With or Without Cetuximab in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
• A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer
• Phase II Fixed Dose Rate Gemcitabine for Advanced or Metastatic Colorectal Cancer
• Phase II Trial Assessing Efficacy and Toxicity of Capecitabine and Oxaliplatin in the Treatment of Colorectal Cancer
• Oxaliplatin, Irinotecan, and Capecitabine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
• Capecitabine (Xeloda) and Radiation for Patients With Rectosigmoid Carcinoma
• Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal Cancer
• XELOX Plus Cetuximab as First-Line Therapy in Patients With Metastatic Colorectal Cancer
• XELOX III. Xeloda in Combination With Eloxatin for Patients With Advanced or Metastatic Colorectal Cancer
• Patients Preference for Oral or i.v. Therapy
• Randomized Phase III Adjuvant Study for Stage III Colorectal Cancer
• Feasibility Study of mFOLFOX6 in Patients With Advanced Colorectal Cancer
• Phase II Study of Oral S-1 Plus Irinotecan (IRIS) in Patients With Advanced Colorectal Cancer
• Phase I / II Study of Irinotecan (CPT-11) Combined With l-Leucovorin (l-LV) and 5-FU in Patients With Advanced Colorectal Cancer
• Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer
• Intensified Chemotherapy in CRC After Resection of Liver Metastases
• An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
• BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies
• Oxaliplatin, 5-FU and Leucovorin in Combination With Oral Capecitabine for Metastatic Colorectal Cancer
• Bevacizumab Plus Capecitabine (Xeloda) in Patients With Untreated Metastatic Colorectal Cancer
• Safety and Efficacy Study of Combination Therapy With Cetuximab and FOLFOX4 in Patients With Colorectal Cancer
• Safety and Efficacy Study of XELOX vs. Oxaliplatin+5-FU CI as First Line Treatment in Metastatic Colorectal Cancer
• Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer
• Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer
• Phase I Trial of huA33 Plus Chemotherapy in Patients With Metastatic Colorectal Cancer
• Iron Therapy in Colo-Rectal Neoplasm and Iron Deficiency Anemia: Intravenous Iron Sucrose Versus Oral Ferrous Sulphate.
• Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer
• Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer
• Enzastaurin for Patients With Metastatic Colorectal Cancer
• A Randomized Trial of Avastin + Gemcitabine + 5-Fluorouracil (5FU)/Folinic Acid Versus Avastin + Oxaliplatin + 5FU/Folinic Acid in Metastatic Colorectal Cancer
• A Study of the Combination of Pemetrexed and Irinotecan Every Two Weeks in Metastatic Colorectal Cancer
• A Trial Comparing Adjuvant Oral UFT/LV to 5-FU/l-LV in Stage III Colorectal Cancer (JCOG-0205-MF)
• Celebrex With Preoperative Chemoradiation - Rectal Cancer
• Study of Xeloda and Gleevec in Patients With Advanced Solid Tumors
• Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
• Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer
• Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma
• Tumor-Pulsed Dendritic Cells Used as a Tumor Vaccine
• Association of MSI, TS, DPD, MVD and EGFR With Chemosensitivity in Stage IV in Colorectal Cancer
• Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors
• Stage IV Colorectal CA ALIMTA
• An Open Label Phase II Study of Indisulam in Combination With Irinotecan in Patients With Metastatic Colorectal Cancer Who Have Been Previously Treated With 5-Fluorouracil/Leucovorin and Oxaliplatin
• Study of E7070 Combined With Capecitabine to Determine Efficacy and Recommended Dose of Combination in Patients With Metastatic Colorectal Cancer
• Using Positron Emission Tomography to Evaluate the Effects of Bevacizumab on Intra-tumoral Pharmacokinetics of 5-fluorouracil in Metastatic Colorectal Cancer
• Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma
• Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer
• Capecitabine and Gemcitabine in Patients With Metastatic Colorectal Cancer
• Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer
• Oxaliplatin and Capecitabine Versus Follow-up After Resection of Colorectal Liver Metastases
• A Phase I Trial of HDFL48 in Recurrent or Metastatic Colorectal Cancers
• Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL)
• Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM)
• Vitamin D/Calcium Polyp Prevention Study
• A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of Uracil- Tegafur (UFT) Compared With Surgery Alone (NSAS-CC)
• Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients
• Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver
• FLOX in Combination With Cetuximab in First-line Treatment of Colorectal Cancer
• Comparing Irinotecan and 5 FU/FA To 5-FU/FA After Resection Of Liver Metastases For Colorectal Cancer
• A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED)
• Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors
• Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants
• Ursodeoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis (FAP) Patients
• Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer
• EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide
• CONCEPT: Comparison of Oxaliplatin vs Conventional Methods With Calcium/Magnesium in First-Line Metastatic Colorectal Cancer
• A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast, Colorectal and Non-Small Cell Lung Cancer (0683-011)(TERMINATED)
• Trial Comparing Two Strategies of Chemotherapy for Metastatic Colorectal Cancer
• Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)
• Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer
• The Effect of Darbepoetin Upon Rehabilitation for Colorectal Cancer Surgery
• Study of Oxaliplatin, Capecitabine, and Bevacizumab to Treat Older Patients With Colorectal Cancer
• A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer
• Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal Cancer
• S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer
• Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer
• PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study
• A Study to Compare Two Avastin-Based Treatment Regimens for the Treatment of Metastatic Colorectal Cancer
• Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
• Evaluating ABX-EGF Extended Therapy in Subjects With MetastaticColorectal Cancer
• Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer
• Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer
• Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma
• Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer
• GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer
• A Study to Evaluate Avastin in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
• A Study to Evaluate Avastin in Combination With Standard Chemotherapy to Treat Colorectal Cancer
• Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases
• Bevacizumab and Capecitabine as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer
• AZD2171 + Chemotherapy in Advanced NSCLC, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07)
• Neoadjuvant Colorectal Cancer With Unresectable Liver Metastases
• Capecitabine and Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer
• SB-715992 in Treating Patients With Advanced or Metastatic Colorectal Cancer
• Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer
• Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma
• Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer
• Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.
• Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer
• MK0457 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Colorectal Cancer and Other Advanced Solid Tumors (0457-001)
• Bortezomib, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer
• Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
• A Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study
• Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer
• Fluorouracil and Irinotecan With or Without Leucovorin Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
• Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer
• Isolated Hepatic Perfusion With Melphalan in Treating Patients With Unresectable Colorectal Cancer That Has Metastasized to the Liver
• PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer
• Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal Cancer
• Celecoxib in Preventing Polyps in Patients Who Have Undergone Surgery for Stage I Colon Cancer
• Oxaliplatin, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Rectum
• Celecoxib Combined With Fluorouracil and Leucovorin in Treating Patients With Resected Stage III Adenocarcinoma (Cancer) of the Colon
• Neoadjuvant Cetuximab, Fluorouracil, and Pelvic Irradiation in Treating Patients With Locally Advanced or Locally Recurrent Rectal Cancer
• Irinotecan and Celecoxib in Treating Patients With Unresectable or Metastatic Colorectal Cancer
• Intensity-Modulated Radiation Therapy With Incorporated Boost and Capecitabine Before Surgery in Treating Patients With Locally Advanced Rectal Cancer
• Study of the Litx™ System Combined With Chemotherapy in Patients With Colorectal Liver Metastases
• Aroplatin and Capecitabine in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies
• Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Treating Patients Who Are Undergoing Surgical Resection for Locally Advanced Rectal Cancer
• OSI-7904L and Oxaliplatin in Treating Patients With Refractory or Recurrent Advanced Colorectal Cancer
• Neoadjuvant Celecoxib and Capecitabine Combined With Pelvic Irradiation in Treating Patients With Stage II or Stage III Adenocarcinoma (Cancer) of the Rectum
• Irinotecan, Fluorouracil, Leucovorin, and Oxaliplatin as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
• DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma
• Pemetrexed Plus a Comparator Versus a Combination of 2 Comparators in First-Line Treatment of Colorectal Cancer
• Selenium for Prevention of Adenomatous Colorectal Polyps
• Study of the GARFT Inhibitor AG2037 in Patients With Metastatic Colorectal Cancer Who Failed Treatment
• Assessment Of Safety And Efficacy Of SU11248 In Patients With Metastatic Colorectal Cancer Who Have Failed Selected Previous Treatments.
• FR901228 in Treating Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Cancer
• Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer
• Epothilone D as Second-Line Treatment for Patients With Advanced or Metastatic Refractory Colorectal Cancer
• FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum
• Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer
• Fluorouracil, Leucovorin, and Irinotecan in Treating Patients With Recurrent or Refractory Metastatic Unresectable Colorectal Cancer
• Neoadjuvant Radiation Therapy and Capecitabine in Treating Patients With Stage III or Stage IV Colorectal Adenocarcinoma
• A Study of ABT-751 in Patients With Colorectal Cancer
• Study Evaluating EKB-569 in Advanced Colorectal Cancer
• Celecoxib, Leucovorin, Fluorouracil, and Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer
• S0304 Induct Chemo Then Chemo-RT in Pts w/Locally Advanced Adenocarcinoma of the Rectum
• Leucovorin and Fluorouracil With or Without Oxaliplatin Compared to Capecitabine With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer
• Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer
• A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
• A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
• A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
• Photodynamic Therapy With Talaporfin Sodium (LS11) in Treating Patients With Refractory Colorectal Liver Metastases
• Bevacizumab Plus Fluorouracil and Leucovorin in Treating Patients With Locally Advanced or Metastatic Stage IV Colorectal Cancer That Has Progressed After Standard Chemotherapy
• Comparison of Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer
• Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer.
• Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer
• Hepatic Arterial Infusion With Floxuridine and Systemic Irinotecan After Surgery in Treating Patients With Hepatic (Liver) Metastases From Colorectal Cancer
• Study Evaluating MAC-321 in Colorectal Cancer
• Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer
• Oxaliplatin and Bevacizumab (Avastin™) With Either Fluorouracil and Leucovorin or Capecitabine in Treating Patients With Advanced Colorectal Cancer
• Boronophenylalanine-Fructose Complex (BPA-F) and/or Sodium Borocaptate (BSH) Followed By Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver Metastases
• Comparison of Sulindac, Aspirin, and Ursodiol in Preventing Colorectal Cancer
• Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer
• A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer
• Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer
• Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer
• A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies
• Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.
• Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer
• Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer
• Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer
• Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors
• Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer
• Bortezomib in Treating Patients With Metastatic or Recurrent Colorectal Cancer
• Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal Carcinoma
• Tezacitabine and Oxaliplatin for the Treatment of Patients With Metastatic Colorectal Cancer
• Gemcitabine Combined With Mistletoe in Treating Patients With Advanced Solid Tumors
• S0030: Capecitabine in Treating Older Patients W/Metastatic or Recurrent Colorectal Cancer That Cannot Be Surgically Removed
• Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
• A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer
• A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer
• Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer
• Combination Chemotherapy in Treating Patients With Colon Cancer
• GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin
• A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies
• Celecoxib in Preventing Cancer in Patients With Rectal Polyps or Colorectal Neoplasia
• Chemotherapy and Bevacizumab With or Without Radiofrequency Ablation in Treating Unresectable Liver Metastases in Patients With Colorectal Cancer
• Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver
• Safety Study of 90Y-hMN14 to Treat Colorectal Cancer Patients With Limited Residual Disease After Surgery
• Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer
• Imatinib Mesylate in Treating Patients With Stage IV Colorectal Cancer
• Oxaliplatin in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
• Safety Study of 90Y-hMN14 to Treat Colorectal Cancer
• A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer
• Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
• Combination Chemotherapy in Treating Patients With Colorectal Cancer
• For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy
• Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
• Safety Study of the Chemotherapy Modulator PHY906 in Patients With Advanced Colorectal Cancer
• EPO906 Therapy in Patients With Advanced Colorectal Cancer
• A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung, Breast, Colon and Pancreatic Cancer
• A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.
• A Trial of ALIMTA (Pemetrexed) Plus Irinotecan in Patients Who Have Been Previously Treated For Metastatic Colorectal Cancer.
• Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis
• CI-1040 in Treating Patients With Advanced Breast, Colon, Pancreatic, or Non-Small Cell Lung Cancer
• Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis
• Aspirin and/or Folic Acid in Preventing Recurrent Colorectal Polyps
• BMS-247550 in Treating Patients With Metastatic Colorectal Cancer
• Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer
• Rofecoxib After Surgery in Treating Patients With Stage II or Stage III Colorectal Cancer
• NB1011 in Treating Patients With Metastatic or Recurrent Colorectal Cancer
• Combination Chemotherapy in Treating Patients With Advanced or Metastatic Colorectal Cancer
• Surgery With or Without Radiofrequency Ablation Followed by Irinotecan in Treating Patients With Colorectal Cancer That is Metastatic to the Liver
• ZD 1839 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer
• Biological Therapy and Chemotherapy in Treating Patients With Metastatic Kidney Cancer or Colorectal Cancer
• Portal Vein Embolization in Treating Patients With Liver Metastases From Primary Colorectal Cancer
• Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors
• SarCNU in Treating Patients With Recurrent or Metastatic Colorectal Cancer
• Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal Cancer
• Exisulind in Preventing Polyps in Patients With Familial Adenomatous Polyposis
• ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer
• Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
• Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients Following Surgery for Stage III Colorectal Cancer
• Shark Cartilage in Treating Patients With Advanced Colorectal or Breast Cancer
• Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer
• Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated
• Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer
• DHA-Paclitaxel in Treating Patients With Metastatic Colorectal Cancer
• SU006668 in Treating Patients With Advanced Solid Tumors
• Combination Chemotherapy With or Without Chemoembolization in Treating Patients With Colorectal Cancer Metastatic to the Liver (6655)
• Surgery With or Without Chemotherapy and Radiation Therapy in TreatingPatients With Stage I Rectal Cancer
• Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
• BMS-247550 in Treating Patients With Recurrent or Metastatic Colorectal Cancer
• Radiation Therapy and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Patients With Rectal Cancer
• Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer
• Tocladesine in Treating Patients With Recurrent or Progressive Metastatic Colorectal Cancer
• Cetuximab Plus Combination Chemotherapy in Treating Patients With Stage IV Colorectal Cancer
• Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver
• Vaccine Therapy in Treating Patients With Metastatic Cancer
• Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases
• Oxaliplatin Plus Capecitabine in Treating Patients With Colorectal, Appendix, or Small Bowel Cancer
• Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver
• Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer
• Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas
• Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
• Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer
• Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Previously Treated With Irinotecan
• Irinotecan or Fluorouracil Plus Leucovorin in Treating Patients With Previously Treated Metastatic Colorectal Cancer
• Ro 31-7453 in Treating Patients With Recurrent or Refractory Metastatic Colorectal Cancer
• Fluorouracil and Leucovorin With or Without Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer
• Vaccine Therapy in Treating Patients With Stage II or Stage III Colon Cancer That Has Been Removed During Surgery
• Fluorouracil and Biological Therapy in Treating Patients With Metastatic Kidney or Colorectal Cancer
• Irinotecan With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer
• A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
• Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer
• Comparison of Three Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer
• Combination Chemotherapy in Treating Patients With Unresectable Metastatic Colorectal Cancer
• Gemcitabine in Treating Patients With Advanced Colorectal Cancer
• Monoclonal Antibody Therapy and/or Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer
• Combination Chemotherapy Plus Bevacizumab in Treating Patients With Advanced Colorectal Cancer
• Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
• Comparing Two Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer
• Radiation Therapy Plus Chemotherapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum
• Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer
• Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
• Fluorouracil With or Without Mitomycin in Treating Patients With Peritoneal Cancer
• Combination Chemotherapy in Treating Patients With Colorectal Cancer
• Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver
• Chemotherapy Plus IM-862 in Treating Patients With Metastatic Colorectal Cancer
• Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer
• SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
• Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
• Combination Chemotherapy With or Without Irinotecan in Treating Patients With Stage III Colon Cancer
• Second-look Surgery With or Without Intraperitoneal Chemotherapy in Treating Patients With Recurrent Colorectal Cancer
• Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps
• Nitrocamptothecin in Treating Patients With Advanced or Recurrent Colorectal Cancer
• Chloroquinoxaline Sulfonamide in Treating Patients With Stage IV Colorectal Cancer
• S9923 R115777 in Treating Patients With Advanced Colorectal Cancer
• Leucovorin and Fluorouracil Compared With Observation in Treating Patients With Colorectal Cancer That Has Been Surgically Removed
• Rebeccamycin Analog in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
• Cetuximab and Irinotecan in Treating Patients With Advanced Colorectal Cancer
• Eniluracil, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Colorectal Cancer
• Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer
• SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver
• Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery
• PET and CT Scans in Patients With Locally Advanced Primary Rectal Cancer That Can Be Removed During Surgery
• Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients With Metastatic Colorectal Cancer
• Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer
• Fluorouracil-Uracil and Leucovorin in Treating Elderly Patients With Metastatic Colorectal Cancer
• Leucovorin and Fluorouracil With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer
• Eniluracil and Surgery in Treating Patients With Primary or Metastatic Colorectal Cancer
• ISIS 2503 in Treating Patients With Metastatic and/or Locally Recurrent Colorectal Cancer
• Capecitabine and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer
• High-Dose Fluorouracil With or Without Leucovorin Compared With Standard Fluorouracil Plus Leucovorin Following Surgery in Treating Patients With Stage III Colon Cancer
• Radiofrequency Ablation Followed By Hepatic Artery Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver
• Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
• Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors
• Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer
• Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin
• Monoclonal Antibody Plus Chemotherapy in Treating Patients With Advanced Colorectal Cancer That Overexpresses HER2
• Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer
• Fluorouracil With or Without Eniluracil in Treating Patients With Advanced Colorectal Cancer
• Irinotecan in Treating Patients With Colorectal Cancer
• Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
• Irofulven in Treating Patients With Metastatic or Recurrent Colorectal Cancer
• Floxuridine, Dexamethasone, and Irinotecan After Surgery in Treating Patients With Liver Metastases From Colorectal Cancer
• Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
• Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
• Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
• Irinotecan in Treating Patients With Metastatic Colorectal Cancer
• Monoclonal Antibody Therapy Plus Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
• Antineoplaston Therapy in Treating Patients With Metastatic or Unresectable Colon Cancer
• Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer
• Irofulven in Treating Patients With Metastatic Colorectal Cancer
• Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer
• Radiation Therapy Before Surgery Compared With Chemotherapy Plus Radiation After Surgery in Treating Patients With Rectal Cancer That Can Be Surgically Removed
• Sulindac and Plant Compounds in Preventing Colon Cancer
• Radiation Therapy Plus Irinotecan in Treating Patients With Colon Cancer
• Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer
• Combination Chemotherapy in Treating Patients With Recurrent Metastatic Colorectal Cancer
• SWOG-S9635 Fluorouracil Plus Ethynyluracil in Advanced Colorectal Cancer Not Responded to Fluorouracil
• Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer
• Bryostatin 1 in Treating Patients With Metastatic Colorectal Cancer
• Diagnostic Procedure for Identifying Patients With Metastatic Colorectal Cancer
• Chemotherapy in Treating Patients With Solid Tumors
• Biological Therapy With Combination Chemotherapy in Patients With Colorectal Cancer
• Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer
• Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors
• Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer
• Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer
• Radiation Therapy Plus Chemotherapy Before Surgery With or Without Chemotherapy After Surgery in Treating Patients With Rectal Cancer
• Palliative Chemotherapy in Treating Patients With Advanced Colorectal Cancer
• Liver Resection and Floxuridine Plus Fluorouracil and Leucovorin in Treating Patients With Liver Metastases From Colorectal Cancer
• Chemotherapy With Raltitrexed and Fluorouracil in Treating Patients With Advanced Colorectal Cancer
• Combination Chemotherapy and Radiation Therapy in Treating Patients With Colorectal Cancer
• Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal Cancer
• Chemotherapy Via an Implantable Pump Compared With a Subcutaneous Port for Unresectable Liver Metastases in Patients With Resected Colorectal Cancer
• Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
• Intravenous Compared With Intrahepatic Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver
• S9415 Chemotherapy in Patients With Stage II or III Colon Cancer That Has Been Surgically Removed
• Immediate Compared With Delayed Chemotherapy in Advanced Colorectal Cancer Without Signs or Symptoms of Disease
• SWOG-9304 Chemotherapy Plus Radiation Therapy in Treating Patients With Rectal Cancer That Has Been Surgically Removed
• Aspirin in Treating Patients With Colorectal Cancer That Has Been Surgically Removed
• Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed
• Radiation Therapy, Surgery, and Chemotherapy in Treating Patients With Rectal Cancer That Can Be Surgically Removed
• Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer
• Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer
• Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers
• A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver
• Phase II Study of the Role of Anti-CEA Antibody Immunoscintigraphy & Positron Emission Tomography in the Localization of Recurrent Colorectal Carcinoma in Patients With Rising Serum CEA Levels in the Absence of Imageable Disease by Conventional Moda
• A Phase II Study of 5-Fluorouracil Administered as a One Hour Infusion in Combination With Calcium Leucovorin and Interferon Alpha-2A in Advanced Colorectal Cancer